Download Swog Fall 2012 Group Meeting PDF .pdf

File information


Original filename: Download Swog Fall 2012 Group Meeting PDF.pdf

This PDF 1.4 document has been generated by / 3-Heights(TM) PDF Merge Split Shell 4.9.25.3 (http://www.pdf-tools.com), and has been sent on pdf-archive.com on 22/08/2018 at 13:11, from IP address 5.144.x.x. The current document download page has been viewed 526 times.
File size: 12.2 MB (96 pages).
Privacy: public file


Download original PDF file


Download Swog Fall 2012 Group Meeting PDF.pdf (PDF, 12.2 MB)


Share on social networks



Link to this file download page



Document preview


SWOG
FALL 2012 GROUP MEETING

© C.E. Andersen
OCTOBER 17-20, 2012
CHICAGO, ILLINOIS

2 Fall 2012

Welcome to SWOG’s Fall 2012 Meeting!
There sure seems to be lots going on – from national political campaigns, to new
guidelines governing the cooperative groups and forming a new NCI network, to
the transition of SWOG’s leadership. While all of that’s important, nothing is more
important than continuing the work of the group, much of which gets accomplished
at meetings such as this one.
If you’ve got a smart phone, download our mobile guidebook and use it to schedule
your time at the meeting. If you’re a regular Twitter user, use our #SWOG2012fa
hash tag when you tweet from the meeting so your fellow members can stay
informed.
Here’s to a productive and educational Chicago meeting!
Warmly,

Laurence H. Baker, D.O.
Group Chairman

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda 3

Integrating clinical research with care and medical practice
Annetine C. Gelijns, Ph.D.
Chair,
Department of Health Evidence and Policy,
Mount Sinai School of Medicine

Value-based insurance design
A. Mark Fendrick, M.D.

Co-Director,
Center for Value-Based Insurance Design,
University of Michigan

Placebos as treatment for metastatic cancer in clinical trials
Lowell E. Schnipper, M.D.
Clinical Director and
Chief of Hematology/Oncology,
Beth Israel Deaconess Medical Center

Discussant
Rick Bangs, M.B.A.

Chair,
SWOG Patient Advocate Committee

Does health care reform open new possibilities for better integrating clinical research
with patient care and medical practice? For a more rational balance of costs and care
through value-based insurance reimbursement? For more ethical approaches to incorporating placebos into clinical trials? And once the doctors speak to these questions,
what are patients to make of their answers?
Experts from a variety of disciplines and backgrounds will address these issues at the Fall
2012 SWOG Group Meeting plenary session, with a patient advocate as rapporteur for
the event.

Health Care Reform and Clinical Trials
A plenary session - SWOG Fall 2012 Group Meeting

12:15 – 2:45 pm
Friday, October 19

Regency B – D
Hyatt Regency Chicago
SWOG • Leading Cancer Research. Together.

4 Fall 2012

GROUP MEETING INDEX
.PAGE(S)
Plenary Session.................................................................................................................................................................... 3 & 15
Hyatt Regency Chicago Travel and Hotel Information and Hotel Maps.................................................................................. 7-8
Schedule of Events.................................................................................................................................................................13-16
Roster of Committee Speakers..............................................................................................................................................17-18
Administrative Committees......................................................................................................................................................... 19
The Hope Foundation................................................................................................................................................................... 20
Accrual Information (Accrual by Institution and Accrual by Institution and Committee)..................................................23-30
Committee Information
Barlogie-Salmon Myeloma Committee...................................................................................................................15 & 31-34
Board of Governors............................................................................................................................................................. 16
Bone Marrow & Stem Cell Transplantation Committee........................................................................................................15
Breast Committee.................................................................................................................................................15 & 35-42
Cancer Control and Prevention Committees......................................................................................................14-15 & 43-64

Cancer Survivorship Committee..................................................................................................................15 & 43-46

Molecular Epidemiology Committee.................................................................................................................. 14 & 47

Outcomes and Comparative Effectiveness Committee...................................................................................... 14 & 48

Prevention Committee................................................................................................................................. 14 & 49-50

Symptom Control and Quality of Life Committee.........................................................................................14 & 51-52
Clinical Practices Committee............................................................................................................................................... 16
Early Therapeutics Committee.................................................................................................................................... 14 & 65
Gastrointestinal Committee...................................................................................................................................15 & 66-70
Genitourinary Committee......................................................................................................................................16 & 71-74
Gynecologic Committee....................................................................................................................................................... 75
Leukemia Committee.............................................................................................................................................15 & 76-80
Lung Committee....................................................................................................................................................16 & 81-85
Lymphoma Committee...........................................................................................................................................16 & 86-89
Melanoma Committee...........................................................................................................................................15 & 90-93
Pharmaceutical Sciences Committee................................................................................................................................... 16
Radiation Therapy Committee............................................................................................................................................. 16
Surgery Committee.................................................................................................................................................... 15 & 22
Training & Workshops
CRA Clinical Trials Training Course..................................................................................................................................... 13
Clinical Research Associates Continuing Education Workshop.................................................................................... 15 & 22
Clinical Research Associates Open Forum................................................................................................................... 14 & 21
Jeri and Noboru Oishi Symposium.............................................................................................................................. 13 & 21
Special Symposia................................................................................................................................................... 5, 21 & 22
Future Group Meeting Dates....................................................................................................................................................... 94
Group Meeting Supporters................................................................................................................................................... 9 & 96

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda 5

JamesÊHicks,ÊPh.D.

SWOGÊInvestigator
ProfessorÊofÊCancerÊGenomics
ColdÊSpringÊHarborÊLaboratory

SessionÊchair

DanielÊF.ÊHayes,ÊM.D.

SWOG
FallÊ2012Ê
GroupÊMeeting

Special
Symposium:

StuartÊB.ÊPadnosÊProfessorÊofÊBreastÊCancerÊResarch
ClinicalÊDirector,ÊBreastÊOncologyÊProgram
UniversityÊofÊMichigan

CTCs:ÊCurrentÊtechnologyÊandÊfutureÊapplications
HowardÊI.ÊScher,ÊM.D.

ChiefÊofÊGenitourinaryÊOncologyÊand
D.ÊWayneÊCallowayÊChairÊinÊUrologicÊOncology
SidneyÊKimmelÊCenterÊforÊUrologicÊandÊProstateÊCancers
MemorialÊSloan-KetteringÊCancerÊCenter

CirculatingÊtumorÊcellsÊasÊaÊreflectionÊofÊ
Ê
prostateÊcancerÊdiseaseÊbiology
StefanieÊS.ÊJeffrey,ÊM.D.

ChiefÊofÊSurgicalÊOncologyÊand
ProfessorÊofÊSurgery
StanfordÊUniversity

TumorÊheterogeneityÊandÊsingleÊcellÊprofiling

TheÊUseÊofÊ
CirculatingÊTumorÊCellsÊ
inÊCancerÊResearch
Thursday,
OctoberÊ18th
1:00ÊÐÊ2:45Êpm
RegencyÊAÊÐÊB
AllÊSWOGÊmembersÊareÊinvited.
SupportedÊbyÊTheÊHopeÊFoundation

SWOG • Leading Cancer Research. Together.

6 Fall 2012

Go Mobile at the Meeting!
To manage your Group Meeting experience from your
smartphone, download our mobile guidebook.
You’ll be able to plan your day with a personalized
schedule and browse exhibitors, maps and general show
info, all in the palm of your hand.
The guidebook app is compatible with iPhones, iPads,
Android, and Blackberry devices.
To get the app, use your phone’s QR-code reader to scan
the code at right. Or choose one of these methods:
1. Download 'Guidebook' from the Apple App Store or the Android Marketplace OR
2. Go to m.guidebookapp.com from your Blackberry OR
3. Visit guidebookapp.com/getit from your phone's browser.
Once you’ve installed the Guidebook app, search for the SWOG Fall 2012 Group Meeting
Guide in the "download guides" section of the app.

Tweeting the Meeting?
Tag your Group Meeting tweets
with

#SWOG2012fa
We’ll post the live stream of tagged Group Meeting
updates to the SWOG website, for ease of following by
those who couldn’t make it.

Follow SWOG at twitter.com/SWOG. Our username is @SWOG.

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda 7

Chicago Travel & Hotel Information
Hyatt Regency Chicago
151 East Wacker Drive
Chicago, Illinois 60601
Phone: 312-565-1234
Fax: 312-239-4414
Arrival/Departure:
Check-in time is 3:00 p.m. Check-out time is 12:00 noon.
Room amenities include a full bath, hair dryer, ironing
board and iron. The concierge staff serves as a liaison between guests and the hotel and outside services.
Hotel Safety Deposit Boxes:
For your convenience, safety deposit boxes are available
at the front desk for your valuables. Please do not leave
valuables in your room.
Recreational Facilities:
The fitness center offers a variety of exercise equipment,
free weights, treadmills, and more, exclusively for hotel
guests. It is open 24 hours a day.
Hotel Restaurants and Lounges:
• Stetson’s Chop House and Bar provide guests with an
elegant atmosphere specializing in steaks and seafood.
• The Bistro at 151 specializes in a variety of American
and Mediterranean cuisine and offers guests a relaxing atmosphere to enjoy breakfast and lunch.
• DaddyO’s Pub and Piano Bar features snacks and
cocktails.
• J’s Express offers breakfast, lunch or dinner for a
quick meal.
• The BIG Bar features the longest free-standing bar
in North America and specializes in a wide variety of
cocktails, wines, champagnes and cognacs.
• In-room dining is available from 6:00 a.m. - 12:00 a.m.
daily.
Business Center:
The Business Center is located on the Purple level in the
East Tower of the hotel. It is open 24 hours a day, 7 days
a week. The Business Center offers fax machines, computer services, color copies, mail drop, Internet access
and photocopying.
Ground Transportation:
• A taxi ride from O’Hare airport to the hotel is approximately $35.00 one-way.
• A taxi ride from Midway airport to the hotel is approximately $30.00 one-way.



Valet parking at the hotel is $52.00 per day for hotel
guests.

Temperature:
The average high for October is 64 degrees and the average low is 46 degrees.
Area Attractions:
• Adler Planetarium and Astronomy Museum
• Architectural Boat Tours
• Art Institute of Chicago
• Brookfield Zoo
• Chicago ArchiCenter
• Chicago Architecture Foundation
• Chicago Botanic Garden
• Chicago Cultural Center
• Field Museum of National History
• Frank Lloyd Wright Home and Studio
• John G. Shedd Aquarium
• John Hancock Center Observatory
• Millennium Park
• Museum of Contemporary Art
• Museum of Science and Industry
• Rockefeller Memorial Chapel
• Sears Tower Skydeck
Local Restaurants:
(The hotel concierge can assist with reservations and suggestions)
• Alinea - Eclectic
• Atwood Cafe - American
• Billy Goat Tavern - Burgers
• Bistro 110 - Continental
• Cape Cod Room - Seafood
• Charlie Trotters - Eclectic
• Heaven on Seven - American Regional
• Mia Francesca - Italian
• Mon Ami Gabi - French
• Shaw’s Crab House and Blue Crab Lounge - Seafood
• Silver Cloud - American
• Spiaggia - Italian

SWOG • Leading Cancer Research. Together.

8 Fall 2012

HYATT REGENCY CHICAGO
Meeting Rooms/Hotel Services

1
2 3
4 5
6 7
9

8

Business Center
and Package Pick-Up
located on the Purple
Level of the East Tower
(one level below the
Gold Level)

SILVER LEVEL
10

11

15

12

13
14

BLUE LEVEL

16

18
19

17

39

GREEN LEVEL
20
22
23
24

21 25
26

*
29

27

28

SWOG
Registration
Desk

BRONZE LEVEL
31
30

32
33
35

Acapulco, West Tower, Gold Level

7

Addams, West Tower, Silver Level

36

Atlanta, West Tower, Gold Level

20

Buckingham, West Tower, Bronze Level

2

Burnham, West Tower, Silver Level

24

Columbian, West Tower, Bronze Level

37

Columbus A-F, East Tower, Gold Level

38

Columbus G-L, East Tower, Gold Level

27

Comiskey, West Tower, Bronze Level

14

Concierge, East Tower, Blue Level

16

Crystal Ballrooms A-C, West Tower, Green Level

8

DuSable, West Tower, Silver Level

6

Field, West Tower, Silver Level

29

Fitness Center, East Tower, Bronze Level

13

Front Desk, East Tower, Blue Level

21

Gold Coast, West Tower, Bronze Level

22

Haymarket, West Tower, Bronze Level

32

Hong Kong, West Tower, Gold Level

1

Horner, West Tower, Silver Level

4

McCormick, West Tower, Silver Level

35

New Orleans, West Tower, Gold Level

3

Ogden, West Tower, Silver Level

23

Picasso, West Tower, Bronze Level

39

Plaza Ballrooms, East Tower, Green Level

30

Regency Ballrooms A-D, West Tower, Gold Level

34

San Francisco, West Tower, Gold Level

9

Sandburg, West Tower, Silver Level

26

Soldier Field, West Tower, Bronze Level

33

Toronto, West Tower, Gold Level

10

Truffles, West Tower, Blue Level

25

Water Tower, West Tower, Bronze Level

5

Wright, West Tower, Silver Level

28

Wrigley, West Tower, Bronze Level

Restaurants/Bars
37

34 36
38

GOLD LEVEL
WEST TOWER

31

EAST TOWER

SWOG • Leading Cancer Research. Together.

19

151-Bistro, Bar and Club, East Tower, Green Level

15

BIG Bar, East Tower, Blue Level

11

DaddyO’s Pub and Piano Bar, West Tower, Blue Level

18

J’s Express, East Tower, Green Level

12

Pronto Mama’s Italian Kitchen, West Tower, Blue Level

17

Stetson’s Chop House & Bar, East Tower, Green Level

SWOG Group Meeting Agenda 9

CME Credit Information
Procedures for CME Credit
CME credit forms for the Group Meeting are available on pages
95 and 97 of the Group Meeting agenda booklet. Only one form
per person is required to list the CME credits for the entire meeting.
Credits for each committee session are listed on the form.
Forms should be turned in to the Registration Desk before the
desk closes at 12:30 p.m. on October 20, 2012. If the forms are not
turned in to the desk, they can be mailed to the Operations Office the
week following the Group Meeting. The Operations Office will submit
all CME forms to the accrediting institution at one time. Forms will be
submitted 30 days following the meeting. You will then receive
a certificate of completion in the mail following submission and
processing of the CME forms by the accrediting institution.

Group Meeting Target Audience and Educational Objectives
SWOG meets semi-annually to keep its members abreast of Group science.
The target audience for these meetings are Physicians, Nurse Oncologists
and Clinical Research Associates.
The educational objectives of these meetings are: to educate attendees
about active and proposed studies so that they may implement the studies at their local institutions; to educate attendees about new treatments
and prevention strategies that are available; to identify areas that can be
improved in cancer research and study implementation and educate attendees on the best ways to implement the solutions at the local level.
These objectives apply to the following areas: Cancer Control and Prevention, including Outcomes and Comparative Effectiveness Committee,
Symptom Control and Quality of Life Committee, Prevention Committee,
Molecular Epidemiology Committee, Cancer Survivorship Committee and
Harry Hynes Symposium; Genitourinary Committee; Early Therapeutics
Committee; Myeloma Committee; Melanoma Committee; Surgery Committee; Radiation Therapy Committee; Plenary Session; Leukemia Committee; Breast Committee; Gastrointestinal Committee; Lung Committee
and Lymphoma Committee.

SWOG gratefully acknowledges the
support of our CME Commercial Supporters*

Double Platinum Supporters
Eli Lilly & Co.
Platinum Supporters
Amgen
Novartis
Silver Supporters
Genomic Health
Bronze Supporters
Bayer Healthcare Pharmaceuticals
Bristol-Myers Squibb
Eisai
Merck
Sigma-Tau Pharmaceuticals
Varian
*Supporters as of September 10, 2012

Speaker and Planner CME Disclosure Information
Each speaker and planner for The Hope Foundation - CME courses has
been requested to complete a Faculty Disclosure Form prior to the activity.
Information regarding affiliations or interests that might be perceived as a
potential conflict of interest is provided in the agenda book, for everyone
to review.

Continuing Medical Education Credit
The Hope Foundation is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education
for physicians.
The Hope Foundation designates this live activity for a maximum of
22.00 AMA PRA Category 1 Credits™. Physicians should only claim
credit commensurate with the extent of their participation in the activity.

SWOG • Leading Cancer Research. Together.

10 Fall 2012
Disclosure of Relevant Financial Relationships with Commercial Companies
The Hope Foundation endorses the Standards of the Accreditation Council for Continuing Medical Education and the Guidelines of the
American Medical Association.
The Hope Foundation requires that all presentations at CME activities be fair, balanced, free of commercial bias, and fully supported by
scientific evidence.
Everyone who is in a position to control the content of a continuing medical education activity is required to disclose relevant
relationships with commercial companies whose products or services are discussed in educational presentations. The ACCME
considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
Disclosure of a relationship is not intended to suggest bias in any presentation but is made to provide participants with information that
might be of potential importance to their evaluation of a presentation.
All potential conflicts of interest have been resolved prior to this program.
Acknowledging a relevant relationship with the following companies or organizations having a direct interest in the subject of this
presentation include:
Planner/Faculty Member

Nature of Relationship

Christine Ambrosone, Ph.D.

No Disclosures

Laurence Baker, D.O.

No Disclosures

Rick Bangs

No Disclosures

Charles Blanke, M.D.

No Disclosures

Powell Brown, M.D.

No Disclosures

Harry Erba, M.D.

Speaker’s Bureau

Celgene, Novartis, Incyte

Research Grant

Novartis, Sanofi-Aventis, Ambit, Ascenta, Sunesis, Chroma, Eli-Lilly,
Millennium

Company

Carol Fabian, M.D.

No Disclosures

A. Mark Fendrick, M.D.

Consultant

Abbott, AonHewitt, AstraZeneca, Aventis, Blue Shield of CA, BMS,
Center for Medicare and Medicaid Services, Genentech, GSK, Health
Alliance Plan, Highmark BlueCross BlueShield, Merck and Co.,
National Business Coalition on Health, National Pharmaceutical
Council, Neocure Group LLC, Pennsylvania State Trooper’s
Association, Pfizer Inc., POZEN Inc., Precision Health Economics
LLC, Thomson Reuters, TriZetto, zanzors

Speaker’s Bureau

Merck and Co., Pfizer Inc.

Grant Research

Abbott, AstraZeneca, Aventis, Eli Lilly, Genentech, GSK, Merck and
Co., Novartis, Pfizer Inc.

Richard Fisher, M.D.

Consultant

Roche, Millennium and Pfizer

Lawrence Flaherty, M.D.

Consultant

Genentech, BMS, Merck, Celgene, GSK

Speaker’s Bureau

Genentech

Lisa Flynn, M.D.

No Disclosures

James Foran, M.D.

No Disclosures

Shirish Gadgeel, M.D.

Consultant

Boehringer-Ingelheim, Methylgene

Speaker’s Bureau

Eli-Lilly, Pfizer, Genentech

Research Grant

Clovis Oncology, Pfizer, Infinity, Novartis, Genentech, Chugai, Abbott

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda
David Gandara, M.D.

Consultant

Amgen, AstraZeneca, Biodesix, BI, BMS, ImClone, Genentech,
Merck, Novartis, Sanofi-Aventis, Array BioPharma, and Response
Genetics

Research Grant

BMS, ImClone, Genentech, Lilly, Merck, and Novartis.

Annetine Gelijns, Ph.D.

No Disclosures

Heather Greenlee, N.D., Ph.D.

No Disclosures

Kenneth Grossmann, M.D.,
Ph.D.
Dawn Hershman, M.D.

No Disclosures

Johanna Horn

No Disclosures

Gabriel Hortobagyi, M.D.

Consultant

Aly Karsan, M.D., F.R.C.P.C.

No Disclosures

Robert Krouse, M.D.

Consultant

Novartis

Razelle Kurzrock, M.D.

Research Grant

Amgen, Amplimed, Angiochem, Aronex, AstraZeneca, Callisto,
Centocor, Concordia, Enzon, Exelixis, Genentech, Genetics, GSK,
Globomax, GPC Biotech, Hoffman La-Roche, Merck, MGI
Pharmaceuticals, Myriad, NCCN, Nereus, NIH, Novartis, Otsuka,
Pfizer, Ziopharm, and Wyeth.

Honoraria

AACR-MCT, Alfred Mann Foundation, Amgen, ASCO Program
Committee, Cancer Treatment Centers of America, CTRT-EAB,
Exelixis, Georgetown University, Merck, MK&A, Myriad, Novartis,
Optum Heath, Pfizer, Pharmacogenomic Medicine, UTHSCSA,
Yokohama City University and Yonsei Cancer Center.

Consultant

AACR-MCT, Enzon, Health Advances, LLC, Johnson and Johnson,
Merch, SAIC-Frederick, Inc.

Other

CTRC-EAB, Novartis, AACR, ASCO, Amgen, CTCA, CTRC, Exelisix,
IDSC, Georgetown University, Johnson and Johnson, Merck, Mt.
Sinai School of Medicine, Myriad, Norwegian Radium Hospital, Nova
Research Company, Novartis, Potum Health Oncology, Palladian
Partners, Roche, UTHSCSA

No Disclosures

Allergan, Genentech, Novartis, Sanofi-Aventis, and Taivex

Monika Leja, M.D.

No Disclosures

Bryan Luce, Ph.D., M.B.A.

No Disclosures

Thomas Lynch, Jr., M.D.

Consultant/SAB

Merck, BI, Astex

Board of Directors and Stock
Holder

Infinity Pharmaceuticals

Patent Holder

Partners Healthcare

Frank Meyskens, Jr., M.D.

Co-Founder

Cancer Prevention Pharmaceuticals

Carol Moinpour, Ph.D.

No Disclosures

Paul Okunieff, M.D.

No Disclosures

Robert Orlowski, M.D., Ph.D.

Consultant

BMS, Onyx, Celgene, Millennium and Abbott

Research Grant

Celgene, Onyx and BMS

Scott Ramsey, M.D.

No Disclosures

Antoni Ribas, M.D.

Consultant

Regina Santella, Ph.D.

No Disclosures

Amgen, Celgene, Millennium, Genentech-Roche and GSK

SWOG • Leading Cancer Research. Together.

11

12 Fall 2012
Lowell Schnipper, M.D.

No Disclosures

Leonard Sender, M.D.

No Disclosures

Dana Sparks

No Disclosures

Lisa Sparks, Ph.D.

No Disclosures

Ian Thompson, Jr., M.D.

No Disclosures

Joseph Unger

No Disclosures

Courtney Wille

No Disclosures

George Yoo, M.D.

No Disclosures

Jason Zell, D.O., M.P.H.

No Disclosures

Gary Zirpoli, M.A.

No Disclosures

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda

13

SCHEDULE OF EVENTS
WEDNESDAY, OCTOBER 17, 2012
7:00 a.m. – 7:30 a.m.
Gold Level
Room: Regency S Foyer

Medidata RAVE & CRA Clinical
Trials Training Course Check-In

7:30 a.m. – 9:00 a.m.
Gold Level
Room: Regency AB

Medidata RAVE Training

7:30 a.m. – 12:30 p.m.
Gold Level
Room: Regency AB

CRA Clinical Trials Training
Course (Includes Medidata
RAVE Training)

1:30 p.m. – 5:00 p.m.
Gold Level
Room: Regency CD

CRA Clinical Trials Training
Course Practicum

Group Meeting Registration & Information Desk
7:00 a.m. - 5:00 p.m. - East Tower Concourse
Hope Foundation Information Desk
8:00 a.m. - 5:00 p.m. - East Tower Concourse
Exhibits & Complimentary Coffee Service
8:00 a.m. - 4:00 p.m. - Toronto

1:00 p.m. – 4:00 p.m.
SoCRA Certification Exam
Gold Level
Room: Acapulco
4:00 p.m. – 7:00 p.m.
Bronze Level
Room: Haymarket

THURSDAY, OCTOBER 18, 2012

Oncology Research Professionals
Executive Meeting (Committee
Members Only)

Note: The Hope Foundation is accredited by the Accreditation
Council for Continuing Medical Education to provide continuing
medical education for physicians.
The Hope Foundation designates this live activity for a
maximum of 22.00 AMA PRA Category 1 Credits™.
Physicians should only claim credit commensurate with the
extent of their participation in the activity.
NOTE: Gray Areas Indicate Workshops
Bolded Meetings Receive CME Credits

7:00 a.m. – 7:30 a.m.
Gold Level
Room: Regency S Foyer

7:30 a.m. – 7:45 a.m.
Gold Level
Room: Regency AB

7:45 a.m. – 12:30 p.m.
Room: Regency AB

2:00 p.m. – 3:00 p.m.
Gold Level
Room: Acapulco

3:00 p.m. – 4:00 p.m.
Bronze Level
Room: Gold Coast

8:00 a.m. – 10:00 a.m.
Blue Level
Room: Truffles
8:00 a.m. – 11:00 a.m.
Bronze Level
Room: Haymarket

Jeri and Noboru Oishi
Symposium Check-In

Welcome and Information
(Open Session)

Jeri and Noboru Oishi
Symposium (Open Session)
Nursing Committee Special
Session B: QOL Coordinators /
Disease & Discipline and
Research Subcommittee
Nursing Committee Special
Session A: Education & Program
Subcommittee
Cancer Control and Prevention
Executive Council (Committee
Members Only)
Advocates Committee Meeting
(Committee Members Only)

SWOG • Leading Cancer Research. Together.

14 Fall 2012

SCHEDULE OF EVENTS
THURSDAY, OCTOBER 18, 2012
Group Meeting Registration & Information Desk
7:00 a.m. - 5:00 p.m. - East Tower Concourse
Hope Foundation Information Desk
8:00 a.m. - 5:00 p.m. - East Tower Concourse
Exhibits & Complimentary Coffee Service
8:00 a.m. - 4:00 p.m. - Toronto

10:15 a.m. – 12:15 p.m.
SYMPTOM CONTROL AND
Gold Level
QUALITY OF LIFE
Room: Regency C COMMITTEE

12:00 p.m. – 2:00 p.m.
Quality Initiative Meeting
Bronze Level
(Committee Members Only)
Room: Haymarket
12:30 p.m. – 2:00 p.m.
Gold Level
Room: Regency D

3:30 p.m. – 4:30 p.m.
EARLY THERAPEUTICS
Gold Level COMMITTEE
Room: Regency AB
4:00 p.m. – 5:30 p.m.
Head Clinical Research
Gold Level
Associates (Open to Member,
Room: Acapulco
Affiliate and CCOP Head CRAs
Only)
4:00 p.m. – 6:00 p.m.
Bronze Level
Room: Picasso

Conflict of Interest
Committee (Committee
Members Only)

5:30 p.m. – 7:00 p.m.


Hope Foundation Platinum
Reception (Invitation Only)

5:30 p.m. – 7:30 p.m.
MOLECULAR EPIDEMIOLOGY
Gold Level
COMMITTEE
Room: Regency C


Clinical Research Associates
Open Forum

12:45 p.m. – 2:45 p.m.
OUTCOMES & COMPARATIVE
Gold Level
EFFECTIVENESS COMMITTEE
Room: Regency C

1:00 p.m. – 2:45 p.m.
Translational Medicine
Gold Level
Symposium on Circulating
Room: Regency AB
Tumor Cells

2:30 p.m. – 4:30 p.m.
Hope Foundation Annual Board
Gold Level
Meeting (Committee Members
Room: San Francisco
Only)

3:15 p.m. – 5:15 p.m.
PREVENTION COMMITTEE
Gold Level
Room: Regency C

SWOG • Leading Cancer Research. Together.

NOTE: Bolded Meetings Receive CME Credits

SWOG Group Meeting Agenda

15

SCHEDULE OF EVENTS
FRIDAY, OCTOBER 19, 2012
Group Meeting Registration & Information Desk
7:30 a.m. - 5:00 p.m. - East Tower Concourse
Hope Foundation Information Desk
8:00 a.m. - 5:00 p.m. - East Tower Concourse
Exhibits & Complimentary Coffee Service
7:00 a.m. - 12:00 p.m.; 2:45 p.m. - 4:00 p.m. - Toronto

7:15 a.m. – 9:45 a.m.
CANCER SURVIVORSHIP
Bronze Level COMMITTEE
Room: Comiskey
7:30 a.m. – 9:30 a.m.
Green Level
Room: Plaza Ballroom

BARLOGIE-SALMON
MYELOMA COMMITTEE

7:30 a.m. – 9:30 a.m.
MELANOMA COMMITTEE
Green Level
Room: Crystal A
8:00 a.m. – 11:30 a.m.
Green Level
Room: Crystal B

Clinical Research Associates
Continuing Education Workshop

9:30 a.m. – 11:00 a.m.
Bronze Level
Room: Haymarket

Quality Assurance Committee
Meeting (Committee Members
Only)

10:00 a.m. – 11:30 a.m.
Bone Marrow & Stem Cell
Bronze Level
Transplantation Committee
Room: Gold Coast


10:00 a.m. – 12:00 p.m.
CANCER CONTROL AND
Gold Level
PREVENTION OUTREACH
Room: Regency A
(HARRY HYNES
SYMPOSIUM)


10:00 a.m. – 12:00 p.m.
Gold Level
Room: Acapulco

SURGERY COMMITTEE

10:00 a.m. – 12:00 p.m.
Blue Level
Room: Truffles

Imaging Committee (Committee
Members Only)

11:30 a.m. – 12:15 p.m.
Plenary Reception (Light Hors
Gold Level D’oeuvres)
Room: Regency Foyer
12:15 p.m. – 2:45 p.m.
Gold Level
Room: Regency B-D

PLENARY SESSION

3:00 p.m. – 5:00 p.m.
Gold Level
Room: San Francisco

3:00 p.m. – 7:00 p.m.
Green Level
Room: Crystal C

Nurse/CRA Planning Committee
(Committee Members Only)
LEUKEMIA COMMITTEE

3:00 p.m. – 7:00 p.m.
BREAST COMMITTEE
Green Level
Room: Crystal B
5:00 p.m. – 7:00 p.m.
Green Level
Room: Crystal A

GI COMMITTEE

5:00 p.m. – 8:00 p.m.
Bronze Level
Room: Haymarket

SWOG Data & Safety Monitoring
Committee (Committee Members
Only)

6:45 p.m. – 8:00 p.m.
Gold Level
Room: Regency CD

Reception

NOTE: Bolded Meetings Receive CME Credits

SWOG • Leading Cancer Research. Together.

16 Fall 2012

SCHEDULE OF EVENTS
SATURDAY, OCTOBER 20, 2012
Group Meeting Registration & Information Desk
7:30 a.m. - 12:30 p.m. - East Tower Concourse

11:30 a.m. – 3:30 p.m.
Gold Level
Room: Regency C

LYMPHOMA COMMITTEE

Hope Foundation Information Desk
8:00 a.m. - 12:30 p.m. - East Tower Concourse
7:00 a.m. – 8:00 a.m.
Gold Level
Room: Regency B

Board of Governors (Board
Members Only)

8:15 a.m. – 9:45 a.m.
Gold Level
Room: Regency B

Committee Chairs (Committee
Members Only)

8:15 a.m. – 9:45 a.m.
Gold Level
Room: Acapulco

10:15 a.m. – 11:45 a.m.
Gold Level
Room: New Orleans

S0819 Educational Session for
PIs and CRAs (Invitation Only)


10:30 a.m. – 11:30 a.m.
Gold Level
Room: Acapulco

Clinical Practices Committee

10:30 a.m. – 12:00 p.m.
Gold Level
Room: San Francisco

RADIATION THERAPY
COMMITTEE

11:30 a.m. – 3:30 p.m.
Gold Level
Room: Regency A

GU COMMITTEE

11:30 a.m. – 3:30 p.m.
Gold Level
Room: Regency B

LUNG COMMITTEE

Pharmaceutical Sciences
Committee

SWOG • Leading Cancer Research. Together.

NOTE: Bolded Meetings Receive CME Credits

SWOG Group Meeting Agenda

Roster of Committee Speakers
Thursday, October 18, 2012
Outcomes and Comparative Effectiveness Committee, 12:45 p.m. - 2:45 p.m. - Regency C
Adaptive Trial Design - Bryan Luce, Ph.D., M.B.A., Director of United Biosource Corporation

The Generalizability of Phase III Cancer Clinical Trial Standard Arm Treatment Outcomes - Joseph M.
Unger, M.S., SWOG Statistical Center

Prevention Committee, 3:15 p.m. - 5:15 p.m. - Regency C

How Young Adult Research Can Be Embedded Into Studies Being Developed in the SWOG Prevention
Committee - Leonard Sender, M.D., Division Chief, Pediatric Oncology, University of California, Irvine

Molecular Epidemiology Committee, 5:30 p.m. - 7:30 p.m. - Regency C

Supplement Use During an Intergroup Clinical Trial for Breast Cancer (S0221) - Gary Zirpoli, M.A.,
Roswell Park Cancer Institute and the University of Buffalo

Friday, October 19, 2012
Cancer Survivorship Committee, 7:15 a.m. - 9:45 a.m. - Comiskey

How Young Adult Research Can Be Embedded Into Studies Being Developed in the SWOG Cancer
Survivorship Committee - Leonard Sender, M.D., Division Chief, Pediatric Oncology, University of California,
Irvine
Use of Social Media to Recruit into SWOG Studies - Lisa Sparks, Ph.D., Chapman University, University of
California, Irvine
Left Ventricular Strain and Serum Troponin to Predict Cardiac Toxicity from Trastuzumab and
Anthracyclines - Monika Leja, M.D., Division of Cardiovascular Medicine, University of Michigan

Melanoma Committee, 7:30 a.m. - 9:30 a.m. - Crystal A Ballroom

How Young Adult Research Can Be Embedded Into Studies Being Developed in the SWOG Melanoma
Committee - Leonard Sender, M.D., Division Chief, Pediatric Oncology, University of California, Irvine
Discussion on the Imaging Initiative - Kenneth F. Grossmann, M.D., Ph.D., University of Utah

Harry E. Hynes CCOP Symposium, 10:00 a.m. - 12:00 p.m. - Regency A

What is Integrative Oncology - Heather Greenlee, N.D., Ph.D., Columbia University Medical Center
Comparative Effectiveness Research: What is it all about? - Scott Ramsey, M.D., Ph.D., Fred Hutchinson
Cancer Research Center
SWOG • Leading Cancer Research. Together.

17

18 Fall 2012

Roster of Committee Speakers
Surgery Committee, 10:00 a.m. - 12:00 p.m. - Acapulco

Update: New Agents for Melanoma - Lawrence Flaherty, M.D., Professor, Department of HematologyOncology, Karmanos Cancer Institute, Wayne State University
Update: S0820, “A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent
Recurrence of Colorectal Cancers and Adenomas in Patients with Stage I-III Colon Cancer, Phase III”
- Jason Zell, D.O., M.P.H., Assistant Professor, Division of Hematology/Oncology, Departments of Medicine &
Epidemiology, University of California, Irvine
Surgical Quality Overview - Lisa Flynn, M.D., Assistant Professor of Surgery, Director, Surgical ICU Harper
Hospital, Wayne State University School of Medicine

Breast Committee, 3:00 p.m. - 7:00 p.m. - Crystal B Ballroom

How Young Adult Research Can Be Embedded Into Studies Being Developed in the SWOG Breast
Committee - Leonard Sender, M.D., Division Chief, Pediatric Oncology, University of California, Irvine
SWOG Contributions to Pharmacogenomics - Christine Ambrosone, Ph.D., Professor of Oncology, Chair,
Department of Cancer Control and Prevention, Roswell Park Cancer Institute

Leukemia Committee, 3:00 p.m. - 7:00 p.m. - Crystal C Ballroom

From Genetic to Genomic Testing for Myeloid Malignancy - Aly Karsan, M.D., F.R.C.P.C., Integrative
Oncology-Radiation Biology Unit, BC Cancer Agency
How Young Adult Research Can Be Embedded Into Studies Being Developed in the SWOG Leukemia
Committee - Leonard Sender, M.D., Division Chief, Pediatric Oncology, University of California, Irvine

Saturday, October 20, 2012
Lung Committee, 11:30 a.m. - 3:30 p.m. - Regency B

Optimal Therapy for EGFR Mutant NSCLC: Role of Monoclonal Antibodies and Dual Kinase Inhibitors in
Overcoming Resistance - Thomas Lynch, Jr., M.D., Yale Cancer Center, Yale University
MEK Inhibition in the Therapy of KRAS Mutant NSCLC - Shirish Gadgeel, M.D., Karmanos Cancer Institute,
Wayne State University

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda

SWOG ADMINISTRATIVE COMMITTEES
Board of Governors
Chair: Laurence H. Baker, D.O.
Bone Marrow and Stem Cell Transplantation Committee
Chair: Stephen J. Forman, M.D.
Clinical Practices Committee
Chair: Saul E. Rivkin, M.D.
Conflict of Interest Committee
Chair: Vernon K. Sondak, M.D.
Membership Committee
Chair: James K. Weick, M.D.
Pharmaceutical Sciences Committee
Chair: Siu-Fun Wong, Pharm.D.
Professional Review Committee
Chair: Primo N. Lara, Jr., M.D.
Oncology Research Professionals Committee
Chair: Rose B. Ermete, R.N., B.S.N.
Quality Assurance Committee
Chair: Manuel Valdivieso, M.D.
Radiation Therapy Committee
Chair: Paul Okunieff, M.D.
Surgery Committee
Chair: George H. Yoo, M.D.

SWOG • Leading Cancer Research. Together.

19

20 Fall 2012

Your donation
gives hope.
We invest because your work is invaluable to
SWOG and to our common mission of preventing
and treating cancer.
All investors will be entered to win up to $10,000 in outstanding
prizes at the SWOG Reception on Friday, October 19 at 6:45 pm,
Regency Ballroom C, The Hyatt Regency Chicago.
Entries must be received by 12:00 pm on October 19, 2012.
Entrants must be present to win.
The Hope Foundation, a nonprofit organization, is the philanthropic
arm of SWOG, and accepts investments from individuals, corporations
and foundations. In support of SWOG’s mission to eradicate cancer,
90% of all contributions are directly invested in programming.

Hope Foundation Information Desk: Foyer, East Tower Concourse, Thursday - Saturday
Johanna (Jo) Horn, Executive Director | jo@thehopefoundation.org | 734-998-7150 | www.thehopefoundation.org

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda

21

Special Symposia
Jeri and Noboru Oishi Symposium
Thursday, October 18, 2012 - 7:45 a.m. - 12:30 p.m.
Location: Regency AB (Gold Level, West Tower)
Topic: Consent: More Than Just a Piece of Paper
Featured Speakers:
• Ethic/Legal Issues of Consent - Michael Roach, J.D.
• AccrualNet/Recruitment of Underserved Populations - Linda Parreco, R.N., M.S.
• Communication of Consent/Research - Terry Albrecht, Ph.D.
• Explain Consent Template Changes - Jeanne Alder, R.N., M.P.H., C.C.R.P.
• Trials and Tribulation of a Trial Candidate - Susan Steel, B.A.
This activity has been submitted to the Oncology Nursing Society for approval to award contact hours. ONS is accredited as an approver
of continuing nursing education by the American Nurses Credentialing Center’s COA.
Certificates for continuing education credits (CEUs) will be distributed to attendees upon completion and return of their evaluation
sheets. Certificates of attendance will be given for Society of Clinical Research Associates.

Clinical Research Associates Open Forum
Thursday, October 18, 2012 - 12:30 p.m. - 2:00 p.m.
Location: Regency D (Gold Level, West Tower)
Topic: This forum offers an opportunity to get answers to your clinical trial questions and address the science and technical
research issues that challenge us today.
Featured Topics:
• Quality Assurance Audits
• CTCAE/SAE Reporting
• The Wild World of Regulatory Affairs
• Data Management Tips & Tools for CRAs
• Cancer Treatment Modalities
• Specimen Preparation and Shipment
• SWOG Federal & CTI Non-Federal Reimbursement
• Hot Topics in CRA Site Administration

SWOG • Leading Cancer Research. Together.

22 Fall 2012

Special Symposia
CRA Continuing Education Workshop
Friday, October 19, 2012 - 8:00 a.m. - 11:30 a.m.
Location: Crystal B Ballroom (Green Level, West Tower)
Title: Lung Cancer
Featured Speakers:
• Lung Cancer Staging - Jared Acoba, M.D.
• Lung Cancer Translational Medicine - Philip C. Mack, Ph.D.
• New Lung Cancer Trials - David R. Gandara, M.D.
• Roadblocks to Enrollment - Annette Betley, B.S.
• Drug and Skin Toxicities - Siu-Fun Wong, Pharm.D., F.A.S.H.P., F.C.S.H.P.
• Helping Patients Transition to Survivorship - Amita Patel, M.D., C.M.D., M.H.A., C.P.E.
• SWOG Update - Jackie Benedetti, Ph.D.

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda

MEMBERS/AFFILIATES
Arizona, U of (3009)
Arkansas, U of (101)
Highlands Onc Group (10885)
MD Anderson, Florida (10955)
Mercy Hosp Ft Smith (8262)
NEA Baptist Clinic (17124)
NEA Baptist Mem Hosp (11728)
Sacred Heart Med Onc (10549)
BC Cancer Agency (14112)
Baylor College (11988)
Baylor Univ Med Ctr (14205)
Brooke Army Med Ctr (10330)
Madigan Army Med Ctr (11460)
S Georgia Med Ctr (10807)
Cedars-Sinai Med Ctr (14111)
Cincinnati MC, U of (10509)
Central Baptist Hosp (11292)
Good Samaritan Hosp (11488)
City of Hope Med Ctr (10082)
Cleveland Clinic OH (301)
Akron Gen Med Ctr (8217)
Mansfield Gen Hosp (10934)
Colorado, U of (10120)
Mem Hosp, Co Springs (10436)
Poudre Valley Hosp (11190)
Columbia University (10769)
Nyack Hospital (11412)
Orange Reg Med Ctr (10889)
St Luke's-Roosevelt (10892)
Valley Hospital (10926)
Winthrop - Univ Hosp (11492)
Davis, U of CA (10176)
California Ca Ctr (10733)
John Muir Med Ctr (10323)
Loma Linda Univ (10682)
NorthBay Med Ctr (10180)

OG
no En
n-S do
W rse
OG d/
In
Ca
te
nc
rg
er
ro
Pr C
up
ev on
en tro
tio l &
n*
*
To
ta
l

SW

SW
OG

Tr
ea
tm
en
t

Membership Accrual by Institution
All Credited Registrations* (Excluding Correlatives)
July 1, 2011 - June 30, 2012

16
7
0
7
0
1
2
6
9
21
0
0
15
2
31
2
0
10
35
42
0
3
45
3
2
0
2
2
4
1
2
53
4
0
10
0

15
21
0
3
1
2
0
0
6
5
6
1
3
7
2
4
0
0
8
35
8
1
31
4
7
16
1
1
7
3
3
32
0
1
0
0

0
0
2
0
0
0
1
9
0
0
0
0
0
0
0
8
2
0
13
0
7
0
0
6
11
8
0
3
0
0
0
9
0
0
0
2

31
28
2
10
1
3
3
15
15
26
6
1
18
9
33
14
2
10
56
77
15
4
76
13
20
24
3
6
11
4
5
94
4
1
10
2

*Registrations used for membership credit. All SWOG studies (excluding correlatives) and SWOG Endorsed registrations count toward SWOG minimum accrual requirements.
**Includes S0702 and S1105.

SWOG • Leading Cancer Research. Together.

23

24 Fall 2012

Sierra Nevada Mem (10890)
St Elizabeth's MC (11173)
Sutter Hlth CRG-East (10712)
Sutter Hlth Western (10714)
Fox Chase Cancer Ctr (13926)
Galveston, U of TX (601)
H Lee Moffitt CC (11898)
Broward Gen Med Ctr (11938)
Leesburg Reg Med Ctr (14513)
Martin Memorial CC (11941)
Space Coast Med Asso (11930)
St Joseph's/Candler (11980)
Watson Clinic Center (11935)
Harrington CC (11446)
Henry Ford Hosp (501)
Breslin Cancer Ctr (10415)
Irvine, U of CA (10498)
Long Beach Mem MC (10617)
Northridge Hosp (11580)
Presbyterian Hosp (11524)
St Jude Medical Ctr (11553)
KaiserPermanenteNCAL (13655)
KaiserPermanenteCOL (15184)
KaiserPermanenteSCAL (15468)
Kansas, U of (3004)
Good Samaritan Hosp (10628)
Stormont-Vail Health (10496)
Kentucky, U of (10012)
Lahey Clinic Med Ctr (16037)
Loyola University (10080)
Edward Hospital (12848)
Hem-Onc Consultants (10616)
Quad Cities/Genesis (10424)
MD Anderson (11439)
MUSC, Hollings CC (11421)
Lexington Med Ctr (12448)
Methodist Hospital (15225)

OG
no En
n-S do
W rse
OG d/
In
Ca
te
nc
rg
er
ro
Pr C
up
ev on
en tro
tio l &
n*
*
To
ta
l

SW

SW
OG

Tr
ea
tm
en
t

Membership Accrual by Institution
All Credited Registrations* (Excluding Correlatives)
July 1, 2011 - June 30, 2012

0
4
13
0
1
1
15
0
0
1
0
3
0
2
17
7
9
6
1
0
2
11
4
17
33
1
4
36
6
39
4
0
0
80
13
2
1

0
7
0
10
0
2
21
0
0
0
0
1
8
5
3
0
5
0
0
2
1
117
7
58
30
1
1
15
8
16
2
1
1
1
8
0
0

1
1
0
0
0
5
30
9
2
0
16
0
0
12
4
5
0
0
0
0
0
0
0
0
1
1
6
0
5
39
1
0
0
0
2
0
1

1
12
13
10
1
8
66
9
2
1
16
4
8
19
24
12
14
6
1
2
3
128
11
75
64
3
11
51
19
94
7
1
1
81
23
2
2

*Registrations used for membership credit. All SWOG studies (excluding correlatives) and SWOG Endorsed registrations count toward SWOG minimum accrual requirements.
**Includes S0702 and S1105.

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda

Michigan, U of (4700)
Mississippi, Univ of (3012)
NE Alabama Reg MC (12075)
NE Georgia Med Ctr (11339)
Singing River Hosp (12057)
St Joseph Hospital (11546)
Oregon Hlth Sci Univ (4100)
Asante-Rogue Med Ctr (8290)
Good Samaritan Hosp (14039)
Mid-Columbia Med Ctr (15175)
Salem Hospital (8167)
Providence Hosp (3500)
Puget Sound (3007)
Bay Area Hospital (11340)
Columbia Basin Hem (12626)
Harrison Bremerton (11548)
Highline Cancer Ctr (16249)
Minor & James Med (12135)
Rockwood Clinic, PS (11435)
Skagit Valley Hosp (10666)
St Charles Hlth Sys (10359)
St Joseph Hospital (10023)
St Mary Med Ctr (11450)
Wenatchee Valley (8214)
Yakima Valley Mem (10620)
Rochester, Univ of (11400)
Arnot Ogden Med Ctr (13424)
San Antonio, U of TX (2400)
Carolinas Med Ctr (17374)
SW Cancer & Res Ctr (8215)
Sinai Hospital (11184)
TX Oncology-Central (15251)
Thompson Ca Surv Ctr (10427)
So Calif, U of (10138)
Desert Hospital (11205)
St Joseph Med Ctr (10283)
St Louis University (10357)

OG
no En
n-S do
W rse
OG d/
In
Ca
te
nc
rg
er
ro
Pr C
up
ev on
en tro
tio l &
n*
*
To
ta
l

SW

SW
OG

Tr
ea
tm
en
t

Membership Accrual by Institution
All Credited Registrations* (Excluding Correlatives)
July 1, 2011 - June 30, 2012

54
5
0
3
5
0
17
2
1
0
2
8
19
5
1
2
0
0
4
2
7
4
0
1
1
61
1
56
0
5
12
10
2
40
4
3
4

31
2
1
8
4
3
9
1
9
2
1
6
18
0
0
2
1
0
0
2
2
2
5
0
0
21
0
9
1
0
4
0
8
26
10
3
3

2
6
0
9
5
3
0
6
6
0
0
7
3
6
4
10
0
1
0
2
1
0
0
2
0
0
8
6
0
0
0
0
0
1
0
0
5

87
13
1
20
14
6
26
9
16
2
3
21
40
11
5
14
1
1
4
6
10
6
5
3
1
82
9
71
1
5
16
10
10
67
14
6
12

*Registrations used for membership credit. All SWOG studies (excluding correlatives) and SWOG Endorsed registrations count toward SWOG minimum accrual requirements.
**Includes S0702 and S1105.

SWOG • Leading Cancer Research. Together.

25

26 Fall 2012

Christian Hosp NE/NW (11878)
Stanford University (12661)
Tennessee, U of (11441)
Cookeville Reg MC (13433)
Tulane University (1801)
Baton Rouge Clinic (15717)
Univ of Chicago MC (13924)
Univ of Chicago MC (15493)
Univ of Maryland (15076)
Utah, U of (2501)
McKay-Dee Hospital (8082)
St Luke's Mt State (8081)
Utah Valley Reg Med (8315)
Wayne State Univ (2701)
MidMichigan Med Ctr (11812)
Mt Clemens Reg MC (10058)
N Michigan Reg Hosp (10697)
Univ of Louisville (11293)
Yale University (17377)
Member & Affiliate Total
CCOPS/MBCCOPS
Atlanta Reg CCOP (10225)
Bay Area CCOP (10706)
Beaumont CCOP (11434)
Boston MC MBCCOP (16686)
Central IL CCOP (10211)
Columbia River CCOP (10251)
Columbus CCOP (9005)
Dayton CCOP (9006)
Grand Rapids CCOP (9007)
Greenville CCOP (10879)
Gulf Coast MBCCOP (11370)
Hawaii MBCCOP, U of (10781)
Kansas City CCOP (9010)
LSU-New Orleans CCOP (10816)
LSU-Shreveport CCOP (13521)
Michigan CRC CCOP (11110)

OG
no En
n-S do
W rse
OG d/
In
Ca
te
nc
rg
er
ro
Pr C
up
ev on
en tro
tio l &
n*
*
To
ta
l

SW

SW
OG

Tr
ea
tm
en
t

Membership Accrual by Institution
All Credited Registrations* (Excluding Correlatives)
July 1, 2011 - June 30, 2012

0
10
6
2
3
2
1
1
1
19
0
6
3
37
1
1
1
3
4
1112

0
5
8
0
1
1
0
0
0
34
0
6
0
16
3
0
0
0
1
834

1
0
0
1
0
0
0
0
0
27
11
0
3
0
0
1
0
0
0
359

1
15
14
3
4
3
1
1
1
80
11
12
6
53
4
2
1
3
5
2305

22
4
7
2
50
6
27
26
15
18
3
17
23
3
13
72

14
6
19
2
35
3
4
3
5
6
1
16
10
6
3
0

13
4
5
0
53
16
5
16
7
5
5
5
12
0
19
16

49
14
31
4
138
25
36
45
27
29
9
38
45
9
35
88

*Registrations used for membership credit. All SWOG studies (excluding correlatives) and SWOG Endorsed registrations count toward SWOG minimum accrual requirements.
**Includes S0702 and S1105.

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda

Montana CCOP (10891)
New Mexico MBCCOP (11331)
Northwest CCOP (9016)
Ozarks Reg CCOP (10210)
Scott & White CCOP (10940)
Southeast CCC CCOP (11108)
Southern Nevada CCOP (13500)
St Louis CCOP (9015)
Upstate Carolina (10122)
Virginia Mason CCOP (9011)
Wichita CCOP (9017)
CCOP/MBCCOP Total
UCOPS
Baylor College-UCOP (10310)
Henry Ford-UCOP (10703)
LSU-Shreveport UCOP (10704)
Loyola Univ - UCOP (10298)
Michigan, U of-UCOP (11386)
Oklahoma, U of-UCOP (10788)
PSOC UCOP (10300)
So Calif, U of-UCOP (10312)
Urology Ctr of CO (13800)
Utah, U of - UCOP (10313)
UCOP Total
FOREIGN
INCan (15434)
King Faisal Spec Hos (13697)
National Cancer Ctr (15484)
Foreign Total
Other Groups
ACOSOG
AMC
CALGB
ECOG
GOG
NCCTG
NCIC

OG
no En
n-S do
W rse
OG d/
In
Ca
te
nc
rg
er
ro
Pr C
up
ev on
en tro
tio l &
n*
*
To
ta
l

SW

SW
OG

Tr
ea
tm
en
t

Membership Accrual by Institution
All Credited Registrations* (Excluding Correlatives)
July 1, 2011 - June 30, 2012

20
27
17
18
1
55
17
11
13
13
26
526

4
9
26
9
2
8
0
17
9
11
20
248

9
4
18
2
11
21
0
23
4
18
26
317

33
40
61
29
14
84
17
51
26
42
72
1091

2
7
4
3
7
14
8
1
13
25
84

0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0

2
7
4
3
7
14
8
1
13
25
84

10
0
6
16

0
0
0
0

32
15
0
47

42
15
6
63

16
3
254
393
3
185
4

0
0
0
0
0
0
0

0
0
40
63
0
67
0

16
3
294
456
3
252
4

*Registrations used for membership credit. All SWOG studies (excluding correlatives) and SWOG Endorsed registrations count toward SWOG minimum accrual requirements.
**Includes S0702 and S1105.

SWOG • Leading Cancer Research. Together.

27

28 Fall 2012

NCIC-CTG
NSABP
RTOG
Other Groups Total
Grand Total

22
60
18
958
2696

OG
no En
n-S do
W rse
OG d/
In
Ca
te
nc
rg
er
ro
Pr C
up
ev on
en tro
tio l &
n*
*
To
ta
l

SW

SW
OG

Tr
ea
tm
en
t

Membership Accrual by Institution
All Credited Registrations* (Excluding Correlatives)
July 1, 2011 - June 30, 2012

0
0
0
0
1082

0
2
0
172
895

22
62
18
1130
4673

*Registrations used for membership credit. All SWOG studies (excluding correlatives) and SWOG Endorsed registrations count toward SWOG minimum accrual requirements.
**Includes S0702 and S1105.

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda

21
9
1
39
6
10
46
22
4
27
24
33
7
-

1
-

-

5
3
1
23
13
5
1
5
11
3
3
3
8
4

QO
L

12
2
4
16
9
9
-

-

-

4
45
7
-

2
3

-

1
3
1
4

-

2
6
-

7
37
1
22
2

10
1
1
1
12
9

3
1

1
8

6
5
1

19
14
3

-

2
-

7

3
5

-

4
1
5

1
6
6
3
2

Ly
mp
ho
ma
M
ela
no
ma
M
ye
lom
a

10
3

1
3
15
3
2

-

2

3
2
27
7

7
1
2
3
2
2
13
1
13
3
7
-

2
8
2
-

-

8
13

-

5
1
2
6
1
7
8
7
21
13

1
4
1

1
5
11
1

2
1
5
1

1
-

2
1

2
-

10

2

-

2
3
2

4
1
2
3

-

1
4
1
-

1
1
2
3

1
-

-

7

1
1

3

3
-

-

-

-

-

1

3
1

2
1

1
1
-

-

-

-

-

2
3
1
5

1
1
6
6
16
1

8

1
-

-

15

-

1

2

9
4

17

1
7

-

-

-

-

6
1

1
2

-

2
-

3

-

-

5
13
-

-

-

1

1
3
-

4

1

Ou
tc
om
es
Pr
ev
en
tio
n
Sy
mp
to
m
Co
nt

ro
l&

-

15
17
29

Le
uk
em
ia
Lu
ng

-

10
7
6
-

3
-

-

10
1
3

N

ur
viv
Ea
or
rly
sh
Th
ip
er
a
p
GI
eu
tic
s

-

-

4
6
1
11
4
19
14
9
6
159
17
11
8
6
3
17
40
9
1
40

Ca
nc
er
S

ea
st

10
10
22
6
9

GY

31
62
49
15
14
26
2
6
31
4
28
33
138
26
56
96
109
25
53
36
147
45
1
8
27
29
9
106
19
38
43
42
26
214
45
78
51
15
9
39
19
106
81
25
2
88

GU

Arizona, U of
Arkansas, U of
Atlanta Reg CCOP
BC Cancer Agency
Bay Area CCOP
Baylor College
Baylor College-UCOP
Baylor Univ Med Ctr
Beaumont CCOP
Boston MC MBCCOP
Brooke Army Med Ctr
Cedars-Sinai Med Ctr
Central IL CCOP
Cincinnati MC, U of
City of Hope Med Ctr
Cleveland Clinic OH
Colorado, U of
Columbia River CCOP
Columbia University
Columbus CCOP
Davis, U of CA
Dayton CCOP
Fox Chase Cancer Ctr
Galveston, U of TX
Grand Rapids CCOP
Greenville CCOP
Gulf Coast MBCCOP
H Lee Moffitt CC
Harrington CC
Hawaii MBCCOP, U of
Henry Ford Hosp
INCan
Irvine, U of CA
KaiserPermanenteNCAL
Kansas City CCOP
Kansas, U of
Kentucky, U of
King Faisal Spec Hos
LSU-New Orleans CCOP
LSU-Shreveport CCOP
Lahey Clinic Med Ctr
Loyola University
MD Anderson
MUSC, Hollings CC
Methodist Hospital
Michigan CRC CCOP

Br

To
ta
l

Membership Accrual by Institution and Committee
All Credited Registrations* (Excluding Correlatives)
July 1, 2011 - June 30, 2012

1
-

12
13
4
5
53
10
10
7
17
16
8
4
13
16
5
7
2
5
57
12
5
9
32
12
7
15
19

5

-

39
2
1
16

*Registrations used for membership credit. Affiliate Accrual Reported with Main Member Institution.

SWOG • Leading Cancer Research. Together.

29

30 Fall 2012

Michigan, U of
Michigan, U of-UCOP
Mississippi, Univ of
Montana CCOP
National Cancer Ctr
New Mexico MBCCOP
Northwest CCOP
Oklahoma, U of-UCOP
Oregon Hlth Sci Univ
Ozarks Reg CCOP
Providence Hosp
Puget Sound
Rochester, Univ of
San Antonio, U of TX
Scott & White CCOP
So Calif, U of
Southeast CCC CCOP
Southern Nevada CCOP
St Louis CCOP
St Louis University
Stanford University
Tennessee, U of
Tulane University
Univ of Chicago MC
Univ of Maryland
Upstate Carolina
Urology Ctr of CO
Utah, U of
Virginia Mason CCOP
Wayne State Univ
Wichita CCOP
Yale University
SWOG Total
ACOSOG
AMC
CALGB
ECOG
GOG
NCCTG
NCIC
NCIC-CTG
NSABP
RTOG
Other Group Total
Grand Total

87
7
54
33
6
40
61
14
56
29
21
115
91
113
14
88
84
17
51
13
15
17
7
2
1
26
13
134
42
63
72
5
3,543
16
3
294
456
3
252
4
22
62
18
1,130
4,673

38
18
9
6
31
31
12
10
3
27
6
27
36
15
1
11
1
9
5
12
-

1

2
1
6

1

6

5
1
3

QO
L

-

7
10
2
8
5
2
2
24
9

14
17
2

-

1

24
13
46
1
12
10
8
6
2

3
1

2
-

1
-

2
2
6
9
1
312
1
14
16
12
1
5
49
361

2
1

13
39
10
13
5
565
32
52
15
2
101
666

3
13
13

Ly
mp
ho
ma
M
ela
no
ma
M
ye
lom
a

5
-

5
1
-

5
18
2
1
2
1
15
1

2
1

3
1
5
5
3
20

1
3
3
149
23
11
34
183

1
1

2
10
34
-

12
14
5
5

1
2

-

2
1
5

1
-

11
2
9
3
2
356
4
28
43
33
2
2
112
468

5
2
6

-

-

2
2
-

2

1
7
3
2

-

-

1
1
4

1

2
1

141
3
52
48
5
1
109
250

106
106

1
1
81

8
-

1
2
12

-

3
38
4
1
46
127

-

1

4
-

1
5

*Registrations used for membership credit. Affiliate Accrual Reported with Main Member Institution.

SWOG • Leading Cancer Research. Together.

-

1
-

2

3
3

2

-

5
-

5
-

-

-

-

10

-

2
-

-

1

1
1
-

4
-

-

-

-

3

1
-

-

Le
uk
em
ia
Lu
ng

N

1
-

2
2
-

-

Ou
tc
om
es
Pr
ev
en
tio
n
Sy
mp
to
m
Co
nt

ro
l&

28
7
1
3

GY

GU

ur
viv
Ea
or
rly
sh
Th
ip
er
a
pe
GI
ut
ics

-

-

35
12
27
16
2
1,091
11
102
185
3
116
4
22
54
10
507
1,598

Ca
nc
er
S

Br

To
ta
l

ea
st

Membership Accrual by Institution and Committee
All Credited Registrations* (Excluding Correlatives)
July 1, 2011 - June 30, 2012

8

12

2
23
9
4
18
12
1
7
29
8
6
11
1
21
22
6
1
4
39
18
1
26
702
40
63
67
2
172
874

SWOG Group Meeting Agenda

31

BARLOGIE-SALMON MYELOMA COMMITTEE
Committee Leadership
Chair:
Vice-Chair:
Executive Officer:
Statisticians:

Scientific Leadership
Translational Medicine:
Radiation:
Surgery:
Pathology:
Early Therapeutics:
Designates
Clinical Research Associates:
CCOP Representative:
Data Coordinators:


Nurses:

Patient Advocate:
Pharmaceutical Science:

Protocol Coordinator:

Robert Z. Orlowski, M.D., Ph.D.
Brian G.M. Durie, M.D.
Harry P. Erba, M.D., Ph.D.
Antje Hoering, Ph.D.
Rachael Sexton, M.S.
Joshua Epstein, D.Sc.
Srinivasan Vijayakumar, M.D.
J. Sybil Biermann, M.D.
Robert B. Lorsbach, M.D., Ph.D.
Frits van Rhee, M.D., Ph.D.
Ellen Chase, B.S.
James D. Bearden, III, M.D.
Jeri Jardine
Laura Kingsbury
Tracy Maher, C.C.R.P.
Steven M. Burt, R.N.
Deborah A. Halk, R.N.
Byron Lee
Lara M. Au, Pharm.D.
Holly O. Chan, Pharm.D.
Sandi Fredette

Time/Location
Friday, October 19, 2012
Room: Plaza Ballroom
7:30 a.m. – 9:30 a.m.
Agenda
Presentations
Active Studies
■■ S0702, “A Prospective Observational Multicenter Cohort Study
to Assess The Incidence of Osteonecrosis of the Jaw (ONJ) in
Cancer Patients with Bone Metastases Starting Zoledronic Acid
Treatment.” Dr. Van Poznak. Activated: 12/15/08.
■■ CTSU/CTN0702, “A Trial of Single Autologous Transplant with
or without Consolidation Therapy versus Tandem Autologous
Transplant with Lenalidomide Maintenance for Patients with
Multiple Myeloma.” Dr. Van Rhee. Activated: 3/15/10.
■■ CTSU/E3A06, Genomic and Immunology Studies for E3A06,
“Randomized Phase III Trial of Lenalidomide versus Observation

Alone in Patients with Asymptomatic Smoldering Multiple
Myeloma.” Dr. Dhodapkar. Activated: 2/1/11.
Closed Studies
■■ S0777, “A Randomized Phase III Trial of CC-5013 (Lenalidomide,
NSC-703813) and Low Dose Dexamethasone (LLD) versus
Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose
Dexamethasone (BLLD) for Induction, in Patients with Previously
Untreated Multiple Myeloma without an Intent for Immediate
Autologous Stem Cell Transplant.” Dr. Durie. Activated:
2/28/08; Closed: 2/1/12.
■■ S0833, “Total Therapy 3 (TT3) for Newly Diagnosed Patients
with Multiple Myeloma (MM): A Southwest Oncology Group Trial
for Patients Aged < 65 Years.” Dr. Abidi. Activated: 4/1/11;
Closed: 5/1/12.
■■ CTSU/E4A08, “A Randomized Phase III Trial of Melphalan and
Dexamethasone (MDex) versus Bortezomib, Melphalan and
Dexamethasone (BMDex) for Untreated Patients with Systemic
Light-chain (AL) Amyloidosis Ineligible for Autologous Stem-cell
Transplantation.” Dr. Zonder. Activated: 12/15/10; Closed:
9/7/12.
Proposed Studies
■■ S1211, “A Phase II Study of Optimal Induction Therapy for
Newly Diagnosed High Risk Multiple Myeloma (HRMM).” Dr.
Usmani.
■■ S1224, “A Phase I/II Study to Evaluate the Safety and Efficacy
of MK-1775 (NSC-XXXX) (Wee1 Kinase Inhibitor) in Combination
with Bortezomib and Pegylated Liposomal Doxorubicin in
Patients with Relapsed and/or Refractory Multiple Myeloma and
Defined p53 Status.” Dr. Abidi.
■■ S1304, “A Phase II Randomized Study Comparing Two Doses
of Carfilzomib (NSC-XXXX) with Dexamethasone for Multiple
Myeloma Patients with Relapsed or Refractory Disease.” Dr.
Ailawadhi.
■■ SXXXX, “Phase III Study of Lenalidomide vs. Lenalidomide +
MLN9708 as Maintenance Therapy Post-Autologous Stem Cell
Transplant in Patients with Multiple Myeloma.” Dr. Shah.
Working Groups
Amyloidosis Working Group update
Waldenström’s Working Group update
Myeloma Translational Medicine Subcommittee update

SWOG • Leading Cancer Research. Together.

32 Fall 2012

BARLOGIE-SALMON MYELOMA COMMITTEE
Publications
The publications below are those that have been received in
published, submitted or accepted form by the Group Chair‘s Office
since the Spring 2012 meeting agenda booklet publication list.
Published/Accepted Manuscripts
■■ Cure models as a useful statistical tool for analyzing survival.
M Othus, B Barlogie, ML LeBlanc, JJ Crowley. Clinical Cancer
Research 18(14):3731-3736, 2012. http://www.ncbi.nlm.nih.
gov/pubmed/22675175.
Submitted Manuscripts
■■ S0120 Clinical predictors of malignancy in monoclonal
gammopathies (SWOG S0120). M Dhodapkar, R Sexton, S
Waheed, S Usmani, B Nair, N Petty, JD Shaughnessy, A Hoering,
J Crowley, R Orlowski, B Barlogie. Blood, submitted 8/16/12.

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda

-

22
17
1
8
1
7
1
-

-

1
4

3
2
-

1
-

1

292
12
2
2
2
18
4
15
9
2
-

S0
77
7

-

S0
12
0

6

7

-

S0
11
5

Arizona, U of
Arkansas, U of
Atlanta Reg CCOP
Baylor College
Boston MC MBCCOP
Boston Univ Med Ctr
Brooke Army Med Ctr
Central IL CCOP
City of Hope Med Ctr
Cleveland Clinic OH
Colorado, U of
Columbia River CCOP
Columbia University
Davis, U of CA
Dayton CCOP
Grand Rapids CCOP
Greenville CCOP
H Lee Moffitt CC
Harrington CC
Hawaii MBCCOP, U of
Henry Ford Hosp
Irvine, U of CA
KaiserPermanenteNCAL
Kansas City CCOP
Kansas, U of
Kentucky, U of
King Faisal Spec Hos
LSU-New Orleans CCOP
LSU-Shreveport CCOP
Loyola University
MD Anderson
Michigan CRC CCOP
Michigan, U of
Mississippi, Univ of
Montana CCOP
New Mexico MBCCOP
Oregon Hlth Sci Univ

E3
A0
6

CT
N0
70
2

Barlogie-Salmon Myeloma Committee
Cumulative Accrual by Institution and Study
For the Period Ending September 6, 2012

2
2
1
15
1
8
20
6
3
6
1
6
2
4
1
13
6
13
6
3
1
1
2
4
19
2
6
7
1

SWOG • Leading Cancer Research. Together.

33

34 Fall 2012

2
1
1
16

7

-

-

-

9
-

2
1

2
3

-

4

-

6
12
104

13
8
7
34
12
7

7

-

8
4

6
-

-

S0
77
7

S0
12
0

-

S0
11
5

Providence Hosp
Puget Sound
Rochester, Univ of
San Antonio, U of TX
So Calif, U of
Southeast CCC CCOP
Southern Nevada CCOP
St Louis CCOP
St Louis University
Tennessee, U of
Tulane University
Upstate Carolina
Utah, U of
Virginia Mason CCOP
Wayne State Univ
Wichita CCOP
CALGB
CTSU-NOS
ECOG
NCCTG
NSABP
RTOG
Total

E3
A0
6

CT
N0
70
2

Barlogie-Salmon Myeloma Committee
Cumulative Accrual by Institution and Study
For the Period Ending September 6, 2012

375

4
8
1
12
17
22
4
158
45
3
2
525

Note: Some studies may not be listed because they were either closed prior to July 1, 2011 or because they are currently
active but have not had any accrual through September 6, 2012.

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda

35

BREAST COMMITTEE
Committee Leadership
Chair:  
Gabriel N. Hortobagyi, M.D.
Vice-Chair:
Julie R. Gralow, M.D.
Executive Officer:
Anne F. Schott, M.D.
Statisticians:
William E. Barlow, Ph.D.

Danika Lew, M.A.
Scientific Leadership
Translational Medicine:
Daniel F. Hayes, M.D.
Radiation Oncology:
TBD
Surgery:
Christine Lee, M.D.
Pathology:
Allen M. Gown, M.D.

Peggy L. Porter, M.D.
Early Therapeutics:
Francisco J. Esteva, M.D., Ph.D.
Designates
Clinical Research Associates: Karyn N. Hart, C.C.R.P.

Pamela A. Williams, R.N., M.S.N.
Cancer Control Liaisons:
Carol J. Fabian, M.D. (Cancer
Survivorship)

Dawn L. Hershman, M.D. (Health
Disparities)

Melanie R. Palomares, M.D.
(Prevention)

Helen K. Chew, M.D. (Symptom

Control & QOL)
CCOP Representative:
David A. Decker, M.D.
Data Coordinators:
Jean Barce

Jennie Barrett

Jeri Jardine

Larry Kaye

Iris Syquia
Nurses:
Dorothy Coleman, R.N., M.S.

Kathy L. Czaplicki, R.N., M.S.N.
Patient Advocate:
Nancy Singleton
Pharmaceutical Science:
Jessie Modlin, Pharm.D.
Protocol Coordinator:
Megan Hardin
Time/Location
Friday, October 19, 2012
Room: Crystal B Ballroom
3:00 p.m. – 7:00 p.m.
Agenda
3:00 – 3:05 p.m.

3:05 – 3:15 p.m.

Welcome and introductions - Gabriel N.
Hortobagyi, M.D. and Julie R. Gralow, M.D.
Publications update - Bill Barlow, Ph.D.

3:15 – 3:30 p.m. How young adult research can be embedded
into studies being developed in the SWOG
Breast Committee - Adolescent and Young
Adult Program - Leonard Sender
3:30 – 3:35 p.m. Q & A
3:35 – 4:00 p.m. Reports from Committee Liaisons
Radiotherapy - Reshma Jagsi
Surgery - J. Gralow/Christine Lee
Cancer Survivorship - Carol Fabian
Health Disparities - Dawn Hershman
S0715
Prevention - Dawn Hershman for Melanie
Palomares
CCOPs - David Decker
4:00 – 4:35 p.m. Update of open SWOG and CTSU trials - All
4:35 – 4:45 p.m. Studies in Development - All
4:45 – 4:50 p.m.
Request for endorsing ACOSOG Z11102 -
Impact of Breast Conservation Surgery on
Surgical Outcomes and Cosmesis in Patients
with Multiple Ipsilateral Breast Cancers
(MIBC). - Gabriel Hortobagyi for Judy
Boughey
Translational Medicine Sub-Committee
Mini-Symposium
Pharmacogenomics and Breast Cancer: A Decade Later.
What Have We Learned? What Should SWOG Do Next?
4:50 – 4:55 p.m.
4:55 – 5:15 p.m.

5:15 – 5:20 p.m.
5:20 – 5:30 p.m.
5:30 – 5:35 p.m.
5:35 – 7:00 p.m.



Introduction - Dan Hayes
SWOG contributions to Pharmacogenomics -
Christine Ambrosone
CYP2D6 Story - Jimmy Rae
Prospective validation trials in SWOG
Q&A
Translational Medicine Working Group Up
dates - Daniel F. Hayes
TM Studies within S0307 - Julie Gralow

Active Adjuvant Studies
■■ S1007, “A Phase III, Randomized Clinical Trial of Standard
Adjuvant Endocrine Therapy +/- Chemotherapy in Patients
with 1-3 Positive Nodes, Hormone-Receptor-Positive and HER2Negative Breast Cancer with Recurrence Score (RS) of 25 or
Less.” Drs. Gonzalez-Angulo, Meric-Bernstam, Hortobagyi, Albain
and Barlow. Activated: 1/15/11.
■■ S1207, “Phase III Randomized, Placebo-Controlled Clinical
Trial Evaluating the Use of Adjuvant Endocrine Therapy +/-

SWOG • Leading Cancer Research. Together.

36 Fall 2012

BREAST COMMITTEE
One Year of Everolimus in Patients with High-Risk, Hormone
Receptor-Positive and HER2/neu Negative Breast Cancer.” Drs.
Chavez-MacGregor, Gonzalez-Angulo. Planned Activation Date:
11/15/12.
■■ CTSU/NSABP B-39, “A Randomized Phase III Study of
Conventional Whole Breast Irradiation (WBI) Versus Partial
Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast
Cancer.” Dr. Pierce. Activated: 3/22/05.
■■ CTSU/NSABP B-43, “A Phase III Clinical Trial Comparing
Trastuzumab Given Concurrently with Radiation Therapy and
Radiation Therapy Alone for Women with HER 2-Positive Ductal
Carcinoma in Situ Resected by Lumpectomy.” Dr. Chung.
Activated: 11/22/08.
■■ CTSU/NSABP B-47, “A Randomized Phase III Trial of Adjuvant
Therapy Comparing Chemotherapy Alone (Six Cycles of TC or
Four Cycles of AC followed by Four Cycles of Weekly Paclitaxel)
to Chemotherapy Plus Trastuzumab in Women with NodePositive or High-Risk Node-Negative HER2-Normal Invasive
Breast Cancer.” Dr. Albain. Activated: 1/7/11.
■■ CTSU/NSABP B-49, “A Phase III Clinical Trial Comparing
the Combination of Docetaxel Plus Cyclophosphamide to
Anthracycline-Based Chemotherapy Regimens for Women with
Node-Positive or High-Risk Node-Negative, HER 2-Negative
Breast Cancer.” Dr. Decker. Activated: 4/9/12.
■■ CTSU/NCIC MA.32, “A Phase III Randomized Trial of Metformin
Versus Placebo on Recurrence and Survival in Early Stage Breast
Cancer.” Dr. Hershman. Activated: 7/8/10.
Active Advanced Disease Studies
■■ S0800, “A Randomized Phase II Trial of Weekly Nanoparticle
Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631)
with or without Bevacizumab, either Preceded by or Followed
by Q2 Week Doxorubicin (A) and Cyclophosphamide (C) plus
Pegfilgrastim (PEG-G) as Neoadjuvant Therapy for Inflammatory
and Locally Advanced HER-2/NEU Negative Breast Cancer.” Drs.
Nahleh, Schott and Hayes. Activated: 4/1/10.

Treated with Single Agent Tamoxifen.” Dr. Lohrisch. Activated:
10/08/10.
Active Cancer Control Studies
■■ S0702, “A Prospective Observational Multicenter Cohort Study
to Assess the Incidence of Osteonecrosis of the Jaw (ONJ)
in Cancer Patients with Bone Metastases Starting Zoledronic
Acid Treatment.” Drs. Van Poznak, Gralow, Schubert, and
Bagramian, Lisa Hansen, R.N. Activated: 12/15/08.
■■ S0812, “A Randomized Double-Blind Placebo-Controlled
Biomarker Modulation Study of Vitamin D in Premenopausal
Women at High Risk for Breast Cancer, Phase IIB.” Drs. Crew
and Hershman. Activated: 11/01/11.
■■ S0927, “A Randomized Placebo-Controlled Trial of Omega3-Fatty Acid for the Control of Aromatase Inhibitor-Induced
Musculoskeletal Pain and Stiffness in Women with Early Stage
Breast Cancer, Phase III.” Drs. Hershman, Crew and Moinpour.
Activated: 2/1/12.
■■ S1008, “Feasibility Study of a Physical Activity and Dietary
Change Weight Loss Intervention in Breast and Colorectal Cancer
Survivors Phase II.” Drs. Greenlee and Hershman. Activated:
3/1/12.
■■ S1105, “Randomized Trial of Text-Messaging Intervention to
Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor
Therapy in Women With Early Stage Breast Cancer.” Drs.
Neugut, Hershman and Ramsey. Activated: 3/27/12.
Closed Studies
■■ S0221, “Phase III Trial of Continuous Schedule AC + G Vs. Q
2 Week Schedule AC, Followed by Paclitaxel Given Either Every
2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant
Therapy in Node-Positive or High -Risk Node-Negative Breast
Cancer.” Drs. Budd and Moore. Activated: 11/1/03; Closed:
1/15/12.

■■ CTSU/E2108, “A Randomized Phase III Trial of Early Local
Therapy for the Intact Primary Tumor in Women with Metastatic
Breast Cancer.” Dr. Christine Lee. Activated: 2/28/11.

■■ S0500, “A Randomized Phase III Trial to Test the Strategy of
Changing Therapy Versus Maintaining Therapy for Metastatic
Breast Cancer Patients Who Have Elevated Circulating Tumor
Cell Levels at First Follow-Up Assessment.” Drs. Smerage
and Hayes. Activated: 10/1/06; Closed: 3/15/12 (initial
registration).

■■ CTSU/E3108, “A Phase II Prospective Trial Correlating PFS with
CYP2D6 Activity in Patients with Metastatic Breast Cancer

■■ S0715, “A Randomized Placebo-Controlled Trial of Acetyl
L-Carnitine (ALC) for the Prevention of Taxane Induced

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda

37

BREAST COMMITTEE
Neuropathy – Phase III.” Drs. Hershman, Albain, Gotay and Lisa
Hansen, R.N., M.S. Activated: 9/15/09; Closed: 2/1/11.

■■ ”Omega-3 Plus Metformin for Breast Cancer Prevention.” Dr.
Crew.

■■ CTSU/CALGB 40601, “Randomized Phase III Trial of Paclitaxel
Combined With Trastuzumab, Lapatinib, or Both as Neoadjuvant
Treatment of HER2-Positive Primary Breast Cancer.” Dr. Henry.
Activated: 12/08/08; Closed: 2/29/12.

■■ “A Randomized Trial of High vs. Standard Dose Vitamin D and
Adherence with Use of Aromatase Inhibitors in the Adjuvant
Setting.” Dr. Khan.

■■ CTSU/NCCTG N0733, “Randomized Phase II Trial of
Capecitabine and Lapatinib With or Without IMC-A12 in Patients
with HER2 Positive Breast Cancer Previously Treated with
Trastuzumab and an Anthracycline and/or a Taxane.” Dr. Linden.
Activated: 7/30/08; Closed: 6/8/12.
■■ CTSU/ACOSOG Z1071, “A Phase II Study Evaluating the Role
of Sentinel Lymph Node Surgery and Axillary Lymph Node
Dissection Following Preoperative Chemotherapy in Women
with Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial
Diagnosis.” Dr. Byrd. Activated: 7/22/09; Closed: 5/29/12.
■■ CTSU/C40603, “Randomized Phase II 2 X 2 Factorial Trial of the
Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly
Paclitaxel Followed by Dose-Dense AC in Hormone ReceptorPoor/HER2-Negative Resectable Breast Cancer.” Dr. Somlo.
Activated: 5/21/10; Closed: 8/31/12.
Studies in Development
■■ S1202, “Phase III Study of Duloxetine for Treatment of
Aromatase Inhibitor-Associated Musculoskeletal Symptoms in
Women with Early Stage Breast Cancer.” Dr. Henry.
New Proposals
■■ “Randomization to Endocrine Therapy Alone Versus Endocrine
Therapy Plus RAD-001 in the Neoadjuvant Setting for ER+
Breast Cancers Based Upon On-Therapy Biologic Response.” Dr.
Sachdev and Massarweh.
■■ “Phase III Trial of Armodafinil for Chemotherapy-Associated
Fatigue and Cognitive Dysfunction.” Dr. Chew.
■■ “Phase II: T-DM1 plus Pertuzumab +/- Paclitaxel in HER
2-Positive Metastatic Breast Cancer.” Dr. Elias.
■■ “PI3K-targeted Therapy in Metastatic Metaplastic/Myoepithelial
Breast cancer- Who DAT?” Dr. Moulder.

■■ “Combined Diet, Exercise and Behavioral Modification
Intervention in Breast Cancer Survivors.” Dr. Klemp.
Publications
The publications listed below are those that have been received in
published, submitted or accepted form by the Group Chair’s Office
since the Spring 2012 meeting agenda booklet publication list.
Published/Accepted Manuscripts
■■ S0226 Combination anastrozole and fulvestrant in metastatic
breast cancer: SWOG S0226. R Mehta, W Barlow, K Albain,
T Vandenberg, S Dakhil, N Tirumali, DL Lew, DF Hayes, JR
Gralow, R Livingston, GH Hortobagyi. New England Journal of
Medicine 367(5):435-444, 2012. http://www.ncbi.nlm.nih.gov/
pubmed/22853014
■■ B-34 (NSABP) Oral clodronate for adjuvant treatment of
operable breast cancer (National Surgical Adjuvant Breast and
Bowel Project protocol B-34: a multicenter, placebo-controlled,
randomized trial. AH Paterson, SJ Anderson, BC Lembersky,
L Fehrenbacher, CI Falkson, KM King, LM Weir, AM Brufsky, S
Dakhil, T Lad, L Baez-Diaz, JR Gralow, A Robidoux, EA Perez,
P Zheng, CE Geyer, SM Swain, JP Costantino, EP Mamounas.
Lancet Oncology,13(7):734-742, 2012 . http://www.ncbi.nlm.
nih.gov/pubmed/22704583
■■ E2197 Prognostic value of biologic subtype and the 21-gene
recurrence score relative to local recurrence after breast
conservation treatment with radiation for early stage breast
carcinoma: results from the Eastern Cooperative Oncology
Group E2197 study. L Solin , R Gray, L Goldstein, A Recht, F
Baehner, S Shak, S Badve, EA Perez, L Shulman S Martino, NE
Davidson, GW Sledge, J Sparano. Breast Cancer Research and
Treatment 134(2):683-692, 2012. http://www.ncbi.nlm.nih.gov/
pubmed?term=solin%20l%20E2197

SWOG • Leading Cancer Research. Together.

38 Fall 2012

BREAST COMMITTEE
Submitted Manuscripts
■■ S0221 First analysis of SWOG S0221: a phase III trial
comparing chemotherapy schedules in high-risk early breast
cancer. GT Budd, W Barlow, HCF Moore, T Hobday, JA
Stewart, C Isaacs, M Salim, J Cho, K Rinn, K Albain, H Chew,
GV Burton, TD Moore, G Srkalovic, BA McGregor, LE Flaherty,
RB Livingston, DL Lew, JR Gralow, GN Hortobagyi. Journal of
Clinical Oncology, pending resubmission in response to reviewers’
comments 8/30/12.
■■ S0715 Randomized double-blind placebo-controlled trial
of acetyl-l-carnitine for the prevention of taxane induced
neuropathy in women undergoing adjuvant breast cancer
therapy. D Hershman, J Unger, K Crew, L Minasian, C
Moinpour, L Hansen, D Lew, L Fehrenbacher, J Wade, S Wong, G
Hortobagyi, F Meyskens, K Albain. Journal of Clinical Oncology,
re-submitted 8/12 (also listed under Symptom Control and
Quality of Life Committee).
■■ MA.27 (NCIC) Exemestane versus anastrozole in postmenopausal
women with early breast cancer. PE Goss, JN Ingle, JW
Chapman, MJ Ellis, GW Sledge, GT Budd, DB Johnson, M
Rabaglio, KI Pritchard, C Elliott, KA Gelmon, LE Shepherd.
Journal of Clinical Oncology, under review, 8/12.

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda

B4
7

-

-

2
4

2

2

1
9
-

20
10
-

4
1

2
4

5

-

C4
01
01
C4
03
02
C4
05
03
C4
06
01
C4
06
03
C7
03
01
E1
10
5
E2
10
8
E3
10
8
IB
C2
4-0
2

B4
3

Arizona, U of
Arkansas, U of
Atlanta Reg CCOP
BC Cancer Agency
Bay Area CCOP
Beaumont CCOP
Boston Univ Med Ctr
Brooke Army Med Ctr
Cedars-Sinai Med Ctr
Central IL CCOP
Cincinnati MC, U of
City of Hope Med Ctr
Cleveland Clinic OH
Colorado, U of
Columbia River CCOP
Columbia University
Columbus CCOP
Davis, U of CA
Dayton CCOP
Galveston, U of TX
Grand Rapids CCOP
Greenville CCOP
Gulf Coast MBCCOP
H Lee Moffitt CC
Harrington CC
Hawaii MBCCOP, U of
Henry Ford Hosp
INCan
Irvine, U of CA
KaiserPermanenteNCAL
Kansas City CCOP
Kansas, U of
Kentucky, U of
King Faisal Spec Hos
LSU-New Orleans CCOP
LSU-Shreveport
LSU-Shreveport CCOP
Lahey Clinic Med Ctr
Los Angeles, U of CA
Loyola University
MD Anderson
MUSC, Hollings CC
Methodist Hospital

B3
9

Breast Committee
Cumulative Accrual by Institution and Study
For the Period Ending September 6, 2012

-

1
2
12
50

1

6
-

1
19
3
2
43
93
69
3
37

-

1
6
3

3
-

2
4
1
5
15
8

11
-

-

-

3

1

-

3
-

-

6

3
2

3

2

-

-

13

1
-

1
-

3

8

2

7
-

-

-

-

1
-

-

-

3
5
-

1
-

10
7
-

-

1
1

-

1
-

1
-

1
-

-

1

-

14

6

2

1

-

1

1
12
3
8
1
9
1
3
3
13
3
5
1

-

9
1
3
4
2
10
26
-

SWOG • Leading Cancer Research. Together.

39

40 Fall 2012

Michigan CRC CCOP
Michigan, U of
Mississippi, Univ of
Montana CCOP
National Cancer Ctr
New Mexico MBCCOP
Northwest CCOP
Oklahoma, Univ of
Oregon Hlth Sci Univ
Ozarks Reg CCOP
Providence Hosp
Puget Sound
Rochester, Univ of
San Antonio, U of TX
Santa Rosa CCOP
Scott & White CCOP
So Calif, U of
Southeast CCC CCOP
Southern Nevada CCOP
St Louis CCOP
St Louis University
Tennessee, U of
Tulane University
Upstate Carolina
Utah, U of
Virginia Mason CCOP
Wayne State Univ
Western Reg CCOP
Wichita CCOP
Yale University
ACOSOG
ANZ BCTG/ IBCSG
CALGB
CTSU-NOS
ECOG
FSS/ IBCSG
GOG
NCCTG
NCIC
NCIC-CTG
NSABP
RTOG
Total

-

-

3
15

8

C4
01
01
C4
03
02
C4
05
03
C4
06
01
C4
06
03
C7
03
01
E1
10
5
E2
10
8
E3
10
8
IB
C2
4-0
2

B4
7

B4
3

B3
9

Breast Committee
Cumulative Accrual by Institution and Study
For the Period Ending September 6, 2012

2
1
1
6
3
2

-

7

-

8
8
1
11
7
32
45
45
3

1

6
12

1

55
733

28

39

4

11

-

-

-

1

7
-

1
1
-

35

-

3
-

1
-

2
15

-

2
1

2

-

5

48

-

3

3
2

1

31

-

-

1

1

4
-

-

-

-

-

-

7

1

-

1

-

1

5
-

-

-

6

-

2

3

1

-

SWOG • Leading Cancer Research. Together.

-

-

-

-

2

1
-

14
-

-

12

17
-

40

25
20
6

9

7

14
1
6
8
3
1
4
3
2
2
6
5
187

SWOG Group Meeting Agenda

Arizona, U of
Arkansas, U of
Atlanta Reg CCOP
BC Cancer Agency
Bay Area CCOP
Beaumont CCOP
Boston Univ Med Ctr
Brooke Army Med Ctr
Cedars-Sinai Med Ctr
Central IL CCOP
Cincinnati MC, U of
City of Hope Med Ctr
Cleveland Clinic OH
Colorado, U of
Columbia River CCOP
Columbia University
Columbus CCOP
Davis, U of CA
Dayton CCOP
Galveston, U of TX
Grand Rapids CCOP
Greenville CCOP
Gulf Coast MBCCOP
H Lee Moffitt CC
Harrington CC
Hawaii MBCCOP, U of
Henry Ford Hosp
INCan
Irvine, U of CA
KaiserPermanenteNCAL
Kansas City CCOP
Kansas, U of
Kentucky, U of
King Faisal Spec Hos
LSU-New Orleans CCOP
LSU-Shreveport
LSU-Shreveport CCOP
Lahey Clinic Med Ctr
Los Angeles, U of CA
Loyola University
MD Anderson
MUSC, Hollings CC
Methodist Hospital

2
3

N0
63
D
N0
73
3
PA
CC
T1
S0
22
1
S0
23
0
S0
50
0
S0
62
2
S0
80
0
S1
00
7
Z1
07
1

JM
A2
0
M
A3
2

Breast Committee
Cumulative Accrual by Institution and Study
For the Period Ending September 6, 2012

10

-

4
7
-

5
17
7

2
-

26

10

19
15
3
19

2
4
3

12
-

-

10

-

1

9

-

9
144
10
2
2
5
7
-

7
2
8
1
7
3
-

2
-

5
93
34

38
56
3
-

3

4
41

29

65

16
23
35
16
16
70
2
71
2
6
24
26
11
68
155
14
51
37
29
24
12
53
33
96
11
-

1

39
8
36
61
35
8
29
77
90
5

2
3
2
1
2
1

27
22
5
107
23
6
30
24
16
66
64
102
-

7

8

17
2

-

-

-

1
1
2
1

1
1

2
7

-

2
13
24
1
4
-

3
2
2

1
-

-

2
-

6
11

3

1
2

9

-

-

1
-

5
3

3
5

-

2

-

7
6
25

-

-

-

-

4

-

7

1

-

8

-

-

3
-

8
1
2
15
8
4

-

21
16
2
2
2
2

3
4
8
10
2
4
6
5
4

6
14
-

2
1
2
1
3
-

-

12
6
21
2
2
8

6
-

2
8
44
4
1

1
6
-

SWOG • Leading Cancer Research. Together.

41

42 Fall 2012

Michigan CRC CCOP
Michigan, U of
Mississippi, Univ of
Montana CCOP
National Cancer Ctr
New Mexico MBCCOP
Northwest CCOP
Oklahoma, Univ of
Oregon Hlth Sci Univ
Ozarks Reg CCOP
Providence Hosp
Puget Sound
Rochester, Univ of
San Antonio, U of TX
Santa Rosa CCOP
Scott & White CCOP
So Calif, U of
Southeast CCC CCOP
Southern Nevada CCOP
St Louis CCOP
St Louis University
Tennessee, U of
Tulane University
Upstate Carolina
Utah, U of
Virginia Mason CCOP
Wayne State Univ
Western Reg CCOP
Wichita CCOP
Yale University
ACOSOG
ANZ BCTG/ IBCSG
CALGB
CTSU-NOS
ECOG
FSS/ IBCSG
GOG
NCCTG
NCIC
NCIC-CTG
NSABP
RTOG
Total

-

24
10

1
-

4

11
10
5
4

1
-

3
3
1
4

3

1
-

10

1

-

-

1

3
4
22
1
7

3
3
8
14

10
473

119

SWOG • Leading Cancer Research. Together.

7

3
66
13
23

-

-

-

-

3

9
22

1

8

-

-

1
-

N0
63
D
N0
73
3
PA
CC
T1
S0
22
1
S0
23
0
S0
50
0
S0
62
2
S0
80
0
S1
00
7
Z1
07
1

JM
A2
0
M
A3
2

Breast Committee
Cumulative Accrual by Institution and Study
For the Period Ending September 6, 2012

31
7
4
73
49
59
6
68
25
12
12
59
6
61
2
66
2
1,712

92
37
12
67

3
2
-

-

32
49
3
44
18
101
10
52
27
47
43
7
13
3
1
42
20
76
6
16
20
324
43
419
1
431
96
32
23
3,294

3
2
2
1

39
28
14
7

9
13
1
6
-

5
3

6
2

-

20

3
1

8
10
15
-

8

5
9
9

5

58
14

13
57

86
46
257

88
62
45
2
624

85

-

-

7
9
1
2
1
2
3

13

-

3

2

-

5
-

-

1

-

5

17
3

-

3

3

-

-

4
-

8
6
1

-

-

-

2
1

-

12
8
1
1
10
4
6

-

7
-

3
-

14
7

-

1
4
9
10

2

2
1

-

13
3
3
2

6
1

3
10
7
12
2
13

6

2
-

9
-

75

9

92

10
1
192

3
29
10
48
1
568

67

Note: Some studies may not be listed because they were either closed prior to July 1, 2011 or
because they are currently active but have not had any accrual through September 6, 2012.

SWOG Group Meeting Agenda

43

CANCER CONTROL & PREVENTION COMMITTEES
Committee Leadership
Assoc. Chair for Cancer
Control & Prevention:
Frank L. Meyskens, Jr., M.D.
CC&P Executive Council Co-Chair: Powel Brown, M.D., Ph.D.
Statisticians:
Garnet Anderson, Ph.D.

William E. Barlow, Ph.D.

Joseph M. Unger, M.S.

Danika Lew, M.A.

Kathryn B. Arnold, M.S.
Scientific Leadership
CCOP Representative:
Mark A. O’Rourke, M.D.
Radiation Therapy Committee:
Louis “Sandy” Constine, M.D.
Surgery Committee:
Robert S. Krouse, M.D., F.A.C.S.
Translational Medicine:
James (Jimmy) Rae, Ph.D.
Liaisons:
Breast Cancer Committee:
Carol J. Fabian, M.D.
(Survivorship)

Helen Chew, M.D. (Symptom

Control & QOL)

Dawn Hershman, M.D., M.S.
(Outcomes)

Melanie Palomares, M.D.
(Prevention)
Gastrointestinal Committee Colon: Jason, Zell, D.O.
Genitourinary Committee:
Peter J. Van Veldhuizen, Jr., M.D.
International Liaison:
Kathy S. Albain, M.D.
Lung Committee:
Gary E. Goodman, M.D.
Lymphoma Committee:
John W. Hayslip, M.D.
Melanoma Committee:
TBD
Designates
Clinical Research Associates:
Connie Szczepanek, R.N., B.S.N.

Susan Majeski, C.C.R.P.

Joyce N. Tull, R.N., B.S.N.

Micheal F. Stephens, C.C.R.A.
Nursing Committee:
Lisa Hansen, R.N., M.S.
Pharmaceutical Science:
Siu-Fun Wong, Pharm.D.
Statistical Center Support:
Stephanie Edwards

Jeri Jardine

Jennie Barrett

Monica Yee

Dona Marrah

Diane Liggett

Roxanne Topacio

Amy Johnson
Patient Advocates:
Daniel M. Moore, Jr., J.D.

Anna Gottlieb

Protocol Coordinator (Outcomes and Comparative
Effectiveness, Prevention, and
Molecular Epidemiology):
Protocol Coordinator (Cancer Survivorship; Symptom
Control and Quality of Life):

Patricia O’Kane
Kimberly Kaberle

Cancer Control and Prevention Executive Council
(Committee Members Only)
Time/Location
Thursday, October 18, 2012
Room: Truffles
8:00 a.m. – 10:00 a.m.
Agenda
8:00 – 8:15 a.m.
8:15 – 8:25 a.m.
8:25 – 8:35 a.m.
8:35 – 8:40 a.m.
8:40 – 8:50 a.m.
8:50 – 9:00 a.m.

Associate Chair Report - F. Meyskens, Jr.
Questions
SWOG and AYA - L. Sender
Questions
Statistical Update - G. Anderson & B. Barlow
Questions
COMMITTEE REPORTS

9:00 – 9:10 a.m.


Prevention Committee
P. Brown/G. Goodman

9:10 – 9:20 a.m.


Cancer Survivorship Committee
C. Fabian/R. Krouse

9:20 – 9:30 a.m.


Symptom Control and QOL Committee
C. Moinpour/J. Wade

9:30 – 9:40 a.m.


Outcomes and Comparative Effectiveness
Committee - D. Hershman/S. Ramsey

9:40 – 9:50 a.m.


Molecular Epidemiology Committee
R. Santella

9:50 – 10:00 a.m.

Pharmacy Update - SF. Wong

SWOG • Leading Cancer Research. Together.

44 Fall 2012

CANCER CONTROL & PREVENTION COMMITTEES
Harry E. Hynes CCOP Symposium (Joint Session)
Time/Location
Friday, October 19, 2012
Room: Regency A
10:00 a.m. – 12:00 p.m.
Agenda
10:00 – 10:05 a.m.

WELCOME - Mark O’Rourke, M.D.

10:05 – 10:15 a.m.


Associate Chair Report
Frank L. Meyskens, Jr., M.D.

10:15 – 10:45 a.m.


What is integrative oncology?
Heather Greenlee, N.D., Ph.D.

10:45 – 10:50 a.m.

Questions

10:50 – 11:10 a.m.



Comparative Effectiveness Research:
What is it all about?
Scott Ramsey, M.D., Ph.D.

11:10 – 11:15 a.m.

Questions

11:15 – 11:40 a.m.
CC&P Committee Updates to
CCOPs
11:40 a.m. – 12:00 p.m. Open Forum for CCOP Investigators

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda

45

CANCER SURVIVORSHIP COMMITTEE
Cancer Survivorship Committee Co-Chairs:
Carol J. Fabian, M.D.
Robert S. Krouse, M.D.
Time/Location
Friday, October 19, 2012
Room: Comiskey
7: 15 a.m. – 9:45 a.m.
Agenda
Introductions and Updates
7:15 - 7:20 a.m. Welcome
Presentations:
7:20 - 7:35 a.m. Dr. Leonard Sender: How young adult research

can be embedded into studies being developed in

the SWOG Cancer Survivorship Committee
7:35 - 7:50 a.m. Dr. Lisa Sparks: Use of Social Media to recruit

into SWOG studies
7:50 - 8:00 a.m. Dr. Monika Leja: Left ventricular strain and

serum troponin to predict cardiac toxicity from

trastuzumab and anthracyclines.
8:00 - 8:10 a.m. Discussion
New Concepts Proposed (at April Meeting) - 10 minutes each
■■ Effect of Everolimus vs Placebo on Intermediate Markers of
Health and Lifespan in Renal Cell Carcinoma Survivors. Drs.
Nicolas Musi and Peter Van Veldhuizen (Secondary Committee
Genitourinary). Update Concept and Probable Funding Source.
■■ Long term effects of Urinary Diversion in Bladder Cancer
Survivors. Dr. Scott Gilbert (Secondary Committee Genitourinary)
Update Concept.
■■ Bowel obstruction from Metastatic Cancer: Dr. Robert Krouse.
Update Concept.
Newly Activated Studies and Update of Concepts Previously
Proposed - 5 minutes each
■■ The Men’s Eating and Living (MEAL) Study: A Randomized
Trial of Diet to Alter Disease Progression in Prostate Cancer
Patients on Active Surveillance. Dr. Van Veldhuizen. Activated:

6/11/11. Cancer Control Credits: 0.2 ($400) at pre-registration;
0.8($1,600) at enrollment. Accrual Update
■■ S1008, “Pilot and Feasibility Study of a Physical Activity
and Dietary Change Weight Loss Intervention in Breast and
Colorectal Cancer Patients.” Dr. Greenlee. Activated: 3/1/12.
Cancer Control Credits: 1.0 ($2,000). Update on accrual – Need
for Eligibility Amendment?
■■ Moderate Dose Vitamin D vs Placebo to Prevent AI Associated
Musculoskeletal Symptoms. Dr. Khan. Study Submitted to
Triage. Update Schema. (Secondary Committee Symptom
Control /QOL).
■■ Change in Impaired Cardiopulmonary Fitness with Graded
Intensity Exercise vs Usual Care in Overweight and Obese Breast
Cancer Survivors. Drs. Klemp, Porter, and Floyd. (Secondary
Committee Breast). Update on Schema and Time Table to
Triage.
■■ Proposed Intergroup A Randomized Controlled Trial of the Impact
of a Telephone-Based Weight Loss Intervention Plus Health
Education Materials versus Health Education Materials Only
upon Invasive Disease Free Survival in Overweight and Obese
Women with Early Stage Breast Cancer. Dr. Korde. (Secondary
Committee Breast ) Update Progress.
Special Projects/ Presentations - 10 minutes each
■■ Rick Bangs: Advocate Update.
■■ Update on SWOG Survivorship Care Plan : Klemp, Lackey, Cook,
Crowley, Anderson ( Secondary Committee is Breast) Present
Design and Source of Support.
■■ International Survivorship Update: Report from the meeting. Dr.
Kathy Albain.
Other Business
Active Studies
■■ Ancillary to S0221 (R01), Antioxidant and CAM Use and
Survival. Drs. Ambrosone and Albain.
■■ S0702, “A Prospective Observational Multicenter Cohort Study
to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in
Cancer Patients with Bone Metastasis Starting Zoledronic Acid
Treatment.” Drs. Van Poznak and Gralow. Activated: 12/15/08.
(Primary Committee Symptom Control).

SWOG • Leading Cancer Research. Together.

46 Fall 2012

CANCER SURVIVORSHIP COMMITTEE
■■ S1008, “Pilot and Feasibility Study of a Physical Activity
and Dietary Change Weight Loss Intervention in Breast and
Colorectal Cancer Patients.” Dr. Greenlee. Activated: 3/1/12.
■■ CTSU/C70807, “The Men’s Eating and Living (MEAL) Study: A
Randomized Trial of Diet to Alter Disease Progression in Prostate
Cancer Patients on Active Surveillance.” Dr. Parsons. Activated:
6/1/11. (Primary Committee Genitourinary)
Closed Studies
■■ S0230, “Phase III Trial of LHRH Analog Administration
During Chemotherapy to Reduce Ovarian Failure Following
Chemotherapy in Early Stage, Hormone-Receptor Negative
Breast Cancer.” Drs. Moore, Albain, and Martino. Activated:
10/1/03; Closed: 6/1/11.
■■ S0715, “Randomized Placebo-Controlled Trial of Acetyl
L-Carnitine For The Prevention Of Taxane-Induced Neuropathy.”
Drs. Hershman, Albain, Gotay and Lisa Hansen, R.N., M.S. (Coassignment to Symptom Control/OOL Committee). Activated:
9/15/09; Closed: 2/1/11.
9:45 Adjourn
Publications
The publications listed below are those that have been received in
published, submitted or accepted form by the Group Chair’s Office
since the Spring 2012 meeting agenda booklet publication list.
Published/Accepted Manuscripts
■■ S0316 A prospective analysis of the influence of older age on
physician decision-making when considering enrollment to breast
cancer clinical trials (SWOG S0316). SH Javid, JM Unger, JR
Gralow, CM Moinpour, AJ Wozniak, JW Goodwin, PN Lara, PA
Williams, LF Hutchins, CC Gotay, KS Albain. The Oncologist
2012 June 20 [Epub ahead of print]. http://www.ncbi.nlm.nih.
gov/pubmed/22723506
Submitted Manuscripts
No publication information for this cycle.

SWOG • Leading Cancer Research. Together.

SWOG Group Meeting Agenda

MOLECULAR EPIDEMIOLOGY COMMITTEE
Molecular Epidemiology Committee Co-Chairs:
Regina M. Santella, Ph.D.

No publication information for this cycle.

Time/Location
Thursday, October 18, 2012
Room: Regency C
5:30 – 7:30 p.m.
Agenda
Presentation
Supplement Use During an Intergroup Clinical Trial for Breast Cancer
(S0221) - Gary Zirpoli, MA Roswell Park Cancer Institute and the
University at Buffalo
Discussion
Closed Studies
S0424, “Molecular Epidemiology Case-Series Study of Non-Small
Cell Lung Cancer in Smoking and Non-Smoking Women and Men.”
Drs. Ambrosone, Santella, Albain, Gumerlock and Reid. Activated:
10/1/05 Closed: 3/15/11. (Santella or Redman report)
Active Studies
■■ S8897 papers – Song Yao
■■ S8897 Grant to examine SNPs in microRNAs in relation to
toxicity and survival. Dr. Yao.
■■ Update on collaboration with Margaret Briehl, Lisa Rimsza
(Translational Medicine) on Variants in Oxidative Stress
Pathways and Lymphoma Outcomes (funded by Hope
Foundation). Dr. Yao.
■■ S0221 Antioxidant study, status of papers (Ambrosone).
■■ S0221 Grant to perform a genome wide scan in relation to
toxicities. Dr. Ambrosone.
■■ PCPT P01Status of studies/papers.
■■ SELECT and PCPT biorepository use requests.
New Business
■■ Examine genetic variants in relation to cisplatin-related toxicities
among patients with colorectal cancer. Drs. Zell and Ambrosone.

SWOG • Leading Cancer Research. Together.

47

48 Fall 2012

OUTCOMES AND COMPARATIVE EFFECTIVENESS
COMMITTEE
Outcomes and Comparative Effectiveness Committee Co-Chairs:
Dawn L. Hershman, M.D., M.S.
Scott D. Ramsey, M.D., Ph.D.
Time/Location
Thursday, October 18, 2012
Room: Regency C
12:45 p.m. – 2:45 p.m.

■■ “A Sero-Epidemiology Survey and Cost-Effectiveness Study of
Screening for HIV, Hepatitis B and Hepatitis C Among Newly
Diagnosed Cancer Patients Among SWOG Affiliated Oncology
Clinics.” Dr. Ramsey.
■■ Grants Submitted
■■ Aligning Genomic Testing with Patient and Physician Preferences
in NSCLC (AGENT-P). Dr. Carlson.

Agenda

Publications

Presentations
“Adaptive Trial Design” - Bryan Luce, Ph.D., M.B.A., Director of
United Biosource Corporation.

The publications listed below are those that have been received in
published, submitted or accepted form by the Group Chair’s Office
since the Spring 2012 meeting agenda booklet publication list.

”The Generalizability of Phase III Cancer Clinical Trial Standard Arm
Treatment Outcomes” - Joseph M. Unger, M.S.

Published/Accepted Manuscripts
■■ The automatic clinical trial: leveraging the electronic medical
record in multisite cancer clinical trials. K Goodman, J
Krueger, J Crowley. Current Oncology Reports 2012 Aug
21 [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/
pubmed?term=goodman%20k%20automatic

Active Studies
■■ S1007, “Update on Quality of Life and Economic Analysis Substudy of Breast protocol S1007.” Bill Barlow, Ph.D.
■■ S1105, “Randomized Controlled Trial of a Behavioral
Intervention to Improve Adherence to Adjuvant Aromatase
Inhibitor Therapy in Women with Early Stage Breast Cancer.”
Drs. Neugut and Hershman. Activated: 3/27/12.
Closed Studies
■■ NexCura Barriers Survey
Ongoing Database projects
■■ Toxicity and survival analysis by gender in Southwest Oncology
Group Trials. Dr. Albain, Joseph M. Unger, M.S. and Carolyn
Gotay, Ph.D. Endpoint/Demographic Factor: Gender – Update on
manuscript status.
Disease type: Multiple
■■ Medicare claims data as a core resource for comparative
effectiveness studies. Dr. Hershman, Joseph M. Unger, M.S.
Disease type: Multiple
■■ Proposed Letter of Intent: Pending CTEP Review

SWOG • Leading Cancer Research. Together.

■■ When progressive disease does not mean treatment failure:
reconsidering criteria for progression. G Oxnard, M Morris, S
Hodi, L Baker, A Venook, L Schwartz. Journal of the National
Cancer Institute 2012 Aug 27 [Epub ahead of print]. http://www.
ncbi.nlm.nih.gov/pubmed/22927506
Submitted Manuscripts
■■ Patient income level and cancer clinical trial participation. J
Unger, D Hershman, K Albain, C Moinpour, J Petersen, K Burg, J
Crowley. Journal of Clinical Oncology, resubmitted 8/31/12.

SWOG Group Meeting Agenda

49

PREVENTION COMMITTEE
Prevention Committee Co-Chairs:
Powel Brown, M.D., Ph.D.
Gary E. Goodman, M.D.
Time/Location
Thursday, October 18, 2012
Room: Regency C
3:15 p.m. – 5:15 p.m.

Closed Studies
■■ S0000, “Selenium and Vitamin E Cancer Prevention Trial
(SELECT).” Drs. Klein, Lippman, Thompson and Lucia.
Activated: 7/25/01; Closed: 6/24/04.
■■ S0000A, “Prevention of Alzheimer’s Disease with Vitamin E and
Selenium (PREADVISE), Phase III Ancillary to S0000 – SELECT.”
Drs. Markesbery and Schmitt. Activated: 5/17/02; Closed:
9/30/09.

Introduction

■■ S0000C, “Prevention of Lung Function Decline with Vitamin E
and Selenium – Respiratory Ancillary Study (RAS) to SELECT.”
Drs. Cassano and Kristal. Activated: 6/4/04; Closed: 5/1/07.

Presentation: “How Young Adult Research Can Be Embedded Into
Studies Being Developed in the SWOG Prevention Committee.” Dr.
Leonard Sender, Division Chief, Pediatric Oncology, University of
California, Irvine.

■■ E5597, “Phase III Chemoprevention Trial of Selenium
Supplementation in Persons with Resected Stage I Non-Small
Cell Lung Cancer.” Dr. Kucuk. Activated: 12/1/00; Closed:
11/5/09.

Panel Discussion: Cancer prevention studies in the adolescent and
young adult population.

■■ S0701, “A Phase III Randomized Trial of Three Antibiotic
Regimens to Eradicate Helicbacter Pylori.” Dr. Greenberg.
Activated: 6/16/09; Closed: 6/30/10.

Agenda

Active Studies
■■ S0812, “A Randomized Double-Blind Placebo-Controlled
Biomarker Modulation Study of Vitamin D in Premenopausal
Women at High-Risk For Breast Cancer, Phase IIB.” Dr. Crew.
Activated: 11/1/11.
■■ S00002, “Centralized Follow-up to Selenium and Vitamin
E Cancer Prevention Trial (SELECT).“ Drs. Klein, Lippman,
Thompson and Lucia. Activated: 11/01/09.
■■ S0000B, “Prevention of Cataract and Age-Related Macular
Degeneration with Vitamin E and Selenium – SELECT Eye
Endpoints (SEE) Phase III Ancillary to S0000 – SELECT.” Drs.
Christen, Glynn and Gaziano. Activated: 7/1/04.
■■ S0000D, “A Study of the Effect of Vitamin E and/or Selenium on
Adenomatous Colorectal Polyps (ACP) in Participants Enrolled
in SELECT, Phase III Ancillary to S0000-SELECT.” Drs. Lance,
Alberts, Battacharyya, Green, and Martinez. Activated: 6/3/08.
■■ S1119, “Gastric Cancer and Helicobacter Pylori Infection in
Lima, Peru: The Role of Water Contamination.” Dr. Valdivieso.
Activated: 12/2/11.

Proposed Studies (on website)
■■ S0820, “A Double-Blind Placebo-Controlled Trial of Eflornithine
and Sulindac to Prevent Recurrence of High Risk Adenomas and
Second Primary Colorectal Cancers in Patients With Stage 0-III
Colon Cancer, Phase III.” Drs. Zell, Brown, Lance, Krouse and
Lipkin. Posted for IRB review: 4/15/11.
New Business
1. Committee re-organization of Molecular Epidemiology and
Prevention Committees (P. Brown, F. Meyskens)
2. Discussion of future prostate cancer prevention trials (P. Brown,
G. Goodman, I. Thompson)
Publications
The publications listed below are those that have been received in
published, submitted or accepted form by the Group Chair’s Office since
the Spring 2012 meeting agenda booklet publication list.
Published/Accepted Manuscripts
■■ S0000A Age expanded normative data for the Ruff 2 & 7
Selective Attention test: evaluating cognition in older males. A
Caban-Holt, E Abner, RJ Kryscio, J Crowley, FA Schmitt. The
Clinical Neuropsychologist 26(5):751-768, 2012. http://www.
ncbi.nlm.nih.gov/pubmed/22651854

SWOG • Leading Cancer Research. Together.

50 Fall 2012

PREVENTION COMMITTEE
■■ S0000A A randomized controlled Alzheimer’s disease prevention
trial’s evolution into an exposure trial. RJ Kryscio, EL Abner, FA
Schmitt, PJ Goodman, M Mendiondo, A Caban-Holt, BC Dennis,
EA Klein, JJ Crowley. Journal of Nutrition, Health and Aging,
accepted 4/4/12.

■■ S9217 Projecting prostate cancer mortality in the PCPT and
REDUCE chemoprevention trials. PF Pinsky, A Black, R Grubb,
ED Crawford, G Andriole, I Thompson, H Parnes. Cancer 2012
Aug 14 [Epub ahead of print] http://www.ncbi.nlm.nih.gov/
pubmed/22893105

■■ S0000 Evaluation of selenium supplementation on the prevention
of bladder cancer in SWOG-coordinated SELECT. Y Lotan,
P Goodman, R Youssef, R Svatek, S Shariat, C Tangen, IM
Thompson, E Klein. Journal of Urology 187(6):2005-2010,
2012. http://www.ncbi.nlm.nih.gov/pubmed?term=lotan%20
y%20selenium

Submitted Manuscripts
■■ S0701 Risk of recurrence and probability of successful
eradication of Helicobacter pylori: one-year results of a
randomized trial in seven Latin American sites (SWOG S0701).
DR Morgan, J Torres, R Sexton, R Herrero, E Salazar-Martinez,
ER Greenberg, LE Bravo, RL Dominguez, C Ferreccio, E LazcanoPonce, MM Meza-Montenegro, EM Pena, R Pena, P Correa, ME
Martinez, WD Chey, M Valdivieso, GL Anderson, GE Goodman,
JJ Crowley, LH Baker. Journal of the American Medical
Association, submitted 8/21/12.

■■ S0000 Moving a randomized clinical trial into an observational
cohort. PJ Goodman, JA Hartline, CM Tangen, JJ Crowley, LM
Minasian, EA Klein, ED Cook, K Anderson, M Yee, FL Meyskens,
LH Baker. Clinical Trials, accepted 8/13/12.
■■ S9217 Associations of serum sex steroid hormones and
5a-androstane-3a,17ß-diol glucuronide concentrations with
prostate cancer risk among men treated with finasteride. AR
Kristal, CA Till, CM Tangen, PJ Goodman, ML Neuhouser, FZ
Stanczyk, LW Chu, SK Patel, IM Thomspon, J Reichardt, AM
Hoque, EA Platz, WD Figg, A van Bokhoven, SM Lippman, AW
Hsing. Cancer Epidemiology Biomarkers and Prevention 2012
Aug 9 [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/
pubmed/22879203
■■ S9217 Prospective study of cytomegalovirus serostatus and
prostate cancer risk in the prostate cancer prevention trial. S
Sutcliffe, C Till, CA Gaydos, FJ Jenkins, P Goodman, A Hoque,
AW Hsing, IM Thompson, JM Zenilman, WG Nelson, AM
DeMarzo, EA Platz. Cancer Causes and Control, 23(9):15111518, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22810146
■■ S9217 Indications for and use of nonsteroidal anti-inflammatory
drugs and the risk of incident, symptomatic benign prostatic
hyperplasia: results from the prostate cancer prevention trial.
JM Schenk, GS Calip, CM Tangen, P Goodman, JK Parsons,
IM Thompson, Kristal AR. American Journal of Epidemiology
176(2):156-1663, 2012. http://www.ncbi.nlm.nih.gov/
pubmed/22759721
■■ S9217 Finasteride reduces the risk of incident symptomatic
benign prostatic hyperplasia. JK Parsons, JM Schenk, KB
Arnold, K Messer, C Till, IM Thompson, A Kristal. European
Urology, 61(6):1263-1270, 2012. http://www.ncbi.nlm.nih.gov/
pubmed/22459892

SWOG • Leading Cancer Research. Together.

■■ S0701 Epidemiology of Helicobacter pylori infection in six Latin
American countries (SWOG trial S0701). C Porras, J Nodora,
R Sexton, R Ferreccio, S Jimenez, RL Dominguez, MP Cook,
GL Anderson, DR Morgan, LH Baker, ER Greenberg, H Herrero.
Cancer Causes and Control, submitted 8/22/12.


Related documents


download swog fall 2012 group meeting pdf
luca gianni
kaye
2016010408 10 48reena nair cv 2016
ming you cv 08 25 2016
cv pantel

Link to this page


Permanent link

Use the permanent link to the download page to share your document on Facebook, Twitter, LinkedIn, or directly with a contact by e-Mail, Messenger, Whatsapp, Line..

Short link

Use the short link to share your document on Twitter or by text message (SMS)

HTML Code

Copy the following HTML code to share your document on a Website or Blog

QR Code

QR Code link to PDF file Download Swog Fall 2012 Group Meeting PDF.pdf